Document:

Exhibit 4.2

[***] - INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES AND EXCHANGE
ACT OF 1934, AS AMENDED.

                              PSIONCOLOGY PTE. LTD.

                                     - and -

                      SINGAPORE GENERAL HOSPITAL PTE. LTD.

                                     - and -

                        SGH TECHNOLOGY VENTURES PTE. LTD

        ================================================================

                             COLLABORATION AGREEMENT

        ================================================================

<PAGE>

THIS AGREEMENT is made as of the 24th day of July 2002

BETWEEN:

1     PSIONCOLOGY PTE. LTD. a company  incorporated  under the laws of Singapore
      and whose  registered  office is at 80  Robinson  Rd,  #17-02,  Singapore,
      068898. ("PSIONCO"); and

2     SINGAPORE  GENERAL HOSPITAL PTE LIMITED a company  incorporated  under the
      laws of  Singapore  and whose  registered  office is at 11 Third  Hospital
      Avenue, #07-00 SNEC Building, Singapore 168751 ("SGH"); and

3     SGH TECHNOLOGY VENTURES PTE LIMITED a company  incorporated under the laws
      of Singapore with  registration  number  200205889D  and whose  registered
      office is at 11 Third Hospital  Avenue,  #07-00 SNEC  Building,  Singapore
      168751 ("SGHT").

PRELIMINARY

(1)   By a  Subscription  and  Shareholders  Agreement  between SGHT,  pSiMedica
      Limited (a company  incorporated under the name of Forceglass Limited on 5
      July, 2000 with a registered number 4027099 and whose registered office is
      at One, St. Paul's  Churchyard,  London EC4M 8SH)  ("PSIMEDICA"),  Biotech
      Research  Ventures  Pte Ltd (a  company  incorporated  under  the  laws of
      Singapore under number 200101402W of registered  office,  24a Duxton Hill,
      Singapore   089607  ("BRV"))  and  pSiOnco,   of  even  date  (the  "SHARE
      SUBSCRIPTION  AGREEMENT"),  it was agreed that SGHT and pSiOnco,  together
      with SGH would execute this Agreement upon its terms and conditions.

(2)   By a Patent and Know-how Licence  Agreement  between (1) pSiMedica and (2)
      pSiOnco of even date,  pSiMedica  granted  pSiOnco a limited licence under
      the pSiOnco Patents and pSiOnco Know-how to research,  discover,  develop,
      manufacture,  have manufactured,  use market and sell within the Field the
      pSiOnco Materials together with the right to grant sub-licences within the
      Field (the "PATENT AND KNOW-HOW LICENCE")

<PAGE>
                                      -2-

NOW IT IS HEREBY AGREED AS FOLLOWS:

1.    DEFINITIONS AND INTERPRETATION

      1.1   In  this  Agreement  and in the  Schedules  to  this  Agreement  the
            following words and phrases shall have the following meanings unless
            the context requires otherwise:

               "Agreement"    the terms and  conditions set out in this document
                              and any and all Schedules and Appendices  attached
                              to it as the same may be varied  from time to time
                              in   accordance   with  the  Change  of   Research
                              Programme Procedure;

               "Board"        the  board  of  directors  for the  time  being of
                              psiOnco;

               "Business
               Day"           a day other  than a  Saturday,  Sunday,  or public
                              holiday in Singapore;

               "Chairman"     the  chairman  of the  Joint  Research  Committee,
                              appointed   in    accordance    with   the   Share
                              Subscription Agreement;

               "Change"       a change to the Research Programme or the services
                              provided  in  accordance  with this  Agreement  to
                              which the Change of Research  Programme  Procedure
                              applies;

               "Change of
               Research
               Programme
               Procedure"     the procedure set out in Clause 14.1 to 14.3;

               "Chemotherapy
               Agents"        Generic  Chlorambucil or its generic  variants and
                              generic   5-Flourouracil   (5FU)  or  its  generic
                              variants and/or such other chemotherapy  agents as
                              agreed   with   pSiOnco   from  time  to  time  in
                              accordance  with the Change of Research  Programme
                              Procedure;

<PAGE>
                                      -3-

               "Commencement
               Date"          the date first written above;

               "Competent
               Authority"     any   local   or   national   agency,   authority,
                              department,   inspectorate,   minister,   ministry
                              official or public or  statutory  person  (whether
                              autonomous  or  not)  of  any  country  or of  any
                              government of any country having jurisdiction over
                              the  Agreement  or any of the  Parties or over the
                              development   or   manufacture   or  marketing  of
                              medicinal  products  including  but not limited to
                              the Health Sciences Authority of Singapore;

               "Documents"    paper, notebooks,  books, files, ledgers, records,
                              tapes,  discs,  diskettes,  CD-ROM  and any  other
                              media on which Know How can be permanently stored;

               "Field"        intra-tumoural radiotherapy using the Radiotherapy
                              Agents  and  chemotherapy  using the  Chemotherapy
                              Agents where the therapy is applied interstitially
                              within  the  tumour  (and not in any other  matter
                              parenterally or otherwise) which for the avoidance
                              of doubt avoids introduction via the vasculature;

               "Force
               Majeure"       in relation to any Party any event or circumstance
                              which is beyond  the  reasonable  control  of that
                              Party,  which that Party could not  reasonably  be
                              expected  to  have  taken  into   account  at  the
                              Commencement  Date and which  results in or causes
                              the failure of that Party to perform any or all of
                              its obligations under this Agreement  including an
                              act  of  God,   lightning,   fire,  storm,  flood,
                              earthquake,  accumulation  of snow or ice, lack of
                              water   arising  from  weather  or   environmental
                              problems,  strike,  lockout  or  other  industrial
                              disturbance  arising in relation to the work force
                              of a Third Party,  war,  terrorist act,  blockade,
                              revolution,  riot  insurrection,  civil commotion,
                              public demonstration,  sabotage, act of vandalism,
                              prevention  from or  hindrance in obtaining in any
                              way   materials,   energy   or   other   supplies,
                              explosion, fault or failure of plant or machinery,
                              governmental  restraint,  act of  legislature  and
                              directive or requirement of a Competent  Authority
                              governing  any Party,  provided that lack of funds
                              shall not be  interpreted  as a cause  beyond  the
                              reasonable control of that Party;

<PAGE>
                                      -4-

               "Group"        in relation to any person, being a corporate body,
                              that  person  any  "subsidiary"  thereof,  or  any
                              "holding  company" thereof or "subsidiary" of such
                              "holding  company" as defined in the Companies Act
                              Cap 50;

               "Intellectual
               Property"      copyright  and related  rights,  database  rights,
                              design rights,  trade marks, trade names,  service
                              marks,  domain  names,  Patent  Rights,  Know How,
                              Materials  and other  such  intellectual  property
                              rights  existing now or in the future  anywhere in
                              the world (whether  registered or not) and any and
                              all applications or renewals for such rights;

               "Joint
               Research
               Committee"     the committee established pursuant to Clause 4;

               "Know How"     unpatented technical and other information related
                              to or  useful  in the  Field  which  is not in the
                              public   domain   including,    ideas,   concepts,
                              inventions,     discoveries,    data,    formulae,
                              specifications,  information relating to Material,
                              procedures for  experiments  and tests and results
                              of   experimentation   and  testing,   results  of
                              research  and  development   including  laboratory
                              records and data analyses;

<PAGE>
                                      -5-

               "Material"     any chemical or biological  substances  related to
                              or useful in the Field including,  but not limited
                              to any:

                                (a)     organic or inorganic chemical element or
                                        compound;

                                (b)     amino acid, amino acid sequence, peptide
                                        or protein;

                                (c)     nucleotide   or   nucleotide    sequence
                                        including DNA and RNA sequences;

                                (d)     vector or construct  including plasmids,
                                        phages or viruses; or

                                (e)     assay or reagent;

               "Parties"      SGH,  pSiOnco  and  SGHT  and a  "Party"  shall be
                              construed accordingly;

               "Patent
               Rights"        to the  extent  related to or useful in the Field,
                              patent applications, patents, author certificates,
                              inventor   certificates,   utility   certificates,
                              improvement patents and models and certificates of
                              addition and all foreign  counterparts of them and
                              includes all divisions,  renewals,  continuations,
                              continuations-in-part,    extensions,    reissues,
                              substitutions,    confirmations,    registrations,
                              revalidations and additions of or to them, as well
                              as any supplementary  protection  certificate,  or
                              like  form  of  protection,   in  respect  thereof
                              existing  now or in  the  future  anywhere  in the
                              world;

<PAGE>
                                      -6-

               "pSiOnco
               Intellectual
               Property"      the pSiOnco  Patent  Rights,  pSiOnco Know How and
                              pSiOnco Material;

               "pSiOnco
               KnowHow"       the Know How in the Field  owned by or licensed to
                              pSiOnco as set out in Schedule 2;

               "pSiOnco
               Material"      the Materials in the Field owned by or licensed to
                              pSiOnco as set out in Schedule 3;

               "pSiOnco
               Patent
               Rights"        the  Patent  Rights  in  the  Field  owned  by  or
                              licensed  to pSiOnco as set out in  Schedule 4 and
                              all Patent Rights arising therefrom;

               "Programme
               Intellectual
               Property"      Any   Intellectual   Property   arising  from  the
                              Research  Programme  carried  out by the  Research
                              Group during the Research Term;

               "Radiotherapy
               Agents"        isotopes of  Phosphorous  and  isotopes of Yitrium
                              and/or such other  agents as agreed  with  pSiOnco
                              from time to time in accordance with the Change of
                              Research Programme Procedure;

               "Research
               Group"         that  part  of  the  Department  of   Experimental
                              Surgery at SGH which is  undertaking  the Research
                              Programme  and  which is  directed  by Dr.  Pierce
                              Chow;

               "Research
               Programme"     the programme of research set out in Schedule 1 as
                              may be  amended  from  time to time in  accordance
                              with the Change of Research Programme Procedure;

<PAGE>
                                      -7-

               "Research
               Term"          the period  during  which the  Research  Programme
                              will be  undertaken  as set out in  Clause  3.1 or
                              such other  period as may be amended  from time to
                              time in  accordance  with the  Change of  Research
                              Programme Procedure;

               "SGHT
               Intellectual
               Property"      the Intellectual  Property owned by or licensed to
                              SGHT and SGH as set out in Schedule 5; and

               "Third
               Party"         any entity or person  other than the  Parties or a
                              member of a Party's Group.

       1.2    In this Agreement:

              1.2.1  unless the context otherwise requires,  all references to a
                     particular  clause or schedule shall be a reference to that
                     clause or  schedule  in or to this  Agreement  as it may be
                     amended from time to time pursuant to this Agreement;

              1.2.2  the  table  of  contents  and  headings  are  inserted  for
                     convenience  only and shall be ignored in  construing  this
                     Agreement;

              1.2.3  unless the contrary intention appears,  words importing the
                     masculine  gender shall include the feminine and vice versa
                     and  words in the  singular  include  the  plural  and vice
                     versa;

              1.2.4  unless  the  contrary  intention  appears,  words  denoting
                     persons shall include any individual, partnership, company,
                     corporation, joint venture, trust association, organisation
                     or  other  entity,  in  each  case  whether  or not  having
                     separate legal personality;

              1.2.5  the words  "include",  "included" or "including"  are to be
                     construed  without  limitation  to  the  specifics  of  the
                     subsequent words;

<PAGE>
                                      -8-

              1.2.6  reference  to  any  statute  or  regulation   includes  any
                     modification or re-enactment of that statute or regulation;
                     and

              1.2.7  references  to each of pSiOnco,  SGH and SGHT shall include
                     references to each of their  permitted  successors in title
                     and assigns.

2.     RESEARCH LICENCES

       2.1    SGHT and SGH hereby  grants to pSiOnco  and SGH any and all rights
              and  permissions  required to  undertake  the  Research  Programme
              whether at the premises of SGH or elsewhere including any licences
              required under any and all SGHT  Intellectual  Property and to the
              extent  that  the  use  of  such  SGHT  Intellectual  Property  is
              necessary to research,  develop,  manufacture,  have manufactured,
              use,  market and sell the Programme  Intellectual  Property,  SGHT
              hereby grants pSiOnco a royalty-free, perpetual licence to use the
              SGHT Intellectual Property for such purposes.

       2.2    pSiOnco  hereby  grants to SGH a  non-transferable,  royalty free,
              non-exclusive  licence under the pSiOnco Intellectual Property and
              any Programme  Intellectual  Property assigned to pSiOnco pursuant
              to Clause 7.1 for the purpose of  carrying  out SGH's tasks in the
              Research Programme within the Field.

3.     RESEARCH PROGRAMME

       3.1    SGH  hereby   undertakes  to  provide  the  services  required  to
              undertake the Research Programme as set out in Schedule 1 (subject
              to any variation  thereto  agreed in writing by SGH and pSiOnco in
              accordance with the Change of Research  Programme  Procedure) with
              all  reasonable  skill and care for a period  of twenty  four (24)
              months from the Commencement Date (the "RESEARCH TERM");

       3.2    In connection with the provision of the services under this Clause
              3 SGH  shall  only use such  employees  or  persons  as have  been
              approved in advance in writing by pSiOnco for these purposes,  and
              SGH  shall  provide  pSiOnco  with  copies of the  resumes  of its
              employees who are to undertake any part of the Research  Programme
              and form part of the Research  Group.  For the  avoidance of doubt
              pSiOnco agrees to the use of the individuals identified by name as
              approved in Schedule 1 who shall form the initial Research Group;

<PAGE>
                                      -9-

       3.3    SGH shall  ensure  that all  employees  or persons  used by SGH to
              perform the Research  Programme  (including,  without  limitation,
              those  in  the  Research  Group)  shall  be  bound  by  provisions
              equivalent  to  those  regarding   confidentiality   (Clause  10),
              publications  (Clause 11),  non-compete (Clause 9.2) and ownership
              of intellectual property (Clause 7) as set out in this Agreement .

       3.4    Each of SGH and pSiOnco  shall keep or cause to be kept  Documents
              relevant  to the  Research  Programme,  such  Documents  shall  be
              maintained separately by SGH from records and notebooks of results
              which are not part of the Research Programme;

       3.5    Unless  otherwise  agreed  between  SGH and  pSiOnco  in  writing,
              neither SGH nor pSiOnco  shall be under any  obligation to provide
              additional  resource or facilities in connection with the Research
              Programme over and above that agreed  pursuant to this Clause 3 or
              as set out in the Research Programme;

       3.6    pSiOnco  acknowledges  that  SGH  is  in  receipt  of  funds  from
              charitable and  governmental  organisations  to carry out research
              and that SGH is  contractually  obliged to carry out that research
              in  accordance  with the relevant  terms of that  funding.  In the
              light of this,  pSiOnco agrees that those  employees of SGH funded
              by the said non-commercial  organisations  shall, at all times, be
              free to pursue the research for which they have been funded and so
              long as research  conducted by members of the Research  Group does
              not conflict with or reduce or in any way diminish any proposed or
              anticipated  contribution  by the  Research  Group to the Research
              Programme.

       3.7    If either of SGH or pSiOnco requires a licence to any Intellectual
              Property owned by a person other than the Parties or any member of
              a Party's Group for the purposes of the Research  Programme,  this
              shall first be discussed by the Joint Research  Committee,  but no
              Party shall enter into a licence  for that  Intellectual  Property
              without  the prior  consent of  pSiOnco.  To the extent  that such
              Intellectual  Property  is owned by a Party  but not  licensed  to
              either SGH or pSiOnco pursuant to this Agreement,  then that Party
              shall, do, or procure to be done, all further acts and execute and
              deliver,  procure to be executed and  delivered,  all such further
              documents and instruments as shall be required in order for SGH or
              pSiOnco to use such Intellectual Property.  Neither Party shall be
              in breach of this  Agreement  where it is unable to carry out part
              of the Research  Programme because to do so without such a licence
              would infringe the Intellectual  Property rights of a person other
              than  the  Parties  unless  they  were  aware of the need for such
              licence at the date of this Agreement.

<PAGE>
                                      -10-

       3.8    SGH shall not delegate to any third party the  performance  of the
              Research Programme without the prior written consent of pSiOnco;

       3.9    SGH shall have no power to enter into any  agreement or accept any
              commitments, liability or similar on behalf of pSiOnco.

4.     JOINT RESEARCH COMMITTEE

       4.1    Immediately  following  the  execution of this  Agreement  SGH and
              pSiOnco shall establish the Joint Research Committee in accordance
              with Clause 4.3 to oversee and manage the Research Programme.

       4.2    The Joint Research  Committee will provide a framework for project
              management  and   communication   between   pSiOnco  and  SGH.  In
              particular, the Joint Research Committee shall:

              4.2.1  subject to the  provisions of this  Agreement and the Share
                     Subscription Agreement allocate the work under the Research
                     Programme as appropriate (taking into account the manpower,
                     facilities  and  equipment  available  to  each  of SGH and
                     pSiOnco);

              4.2.2  monitor  progress  against  the agreed  milestones  and the
                     timetable of the Research Programme;

              4.2.3  promote  and ensure  the due  performance  of the  Research
                     Programme;

<PAGE>
                                      -11-

              4.2.4  advise and assist in the  resolution  of any  scientific or
                     technical  difficulties which are experienced by either SGH
                     or pSiOnco personnel engaged on the Research Programme;

              4.2.5  review the results of the Research Programme with a view to
                     identifying   any   patentable   inventions   and  consider
                     opportunities for publications and patent filings,  subject
                     to  the   provisions  of  this   Agreement  and  the  Share
                     Subscription Agreement;

              4.2.6  prepare quarterly reports for submission to the Board, and

              4.2.7  subject  always to  Clause 2  propose  to the Board and SGH
                     amendments to the Research  Programme  from time to time as
                     may be  necessary  or  desirable  which  shall be agreed in
                     accordance with the Change of Research Programme Procedure;

PROVIDED  ALWAYS that the Joint Research  Committee  shall have no power to bind
either  pSiOnco or SGH and  decisions  reached  by it shall be  treated  only as
proposals  or  recommendations  to the  Board  of  pSiOnco  and  to  SGH  unless
specifically agreed otherwise in writing.

4.3    The Joint  Research  Committee  shall be  established  and run by SGH and
       pSiOnco as follows:-

       4.3.1  The  Joint  Research  Committee  shall  comprise  six (6)  members
              ("Members")  comprising  three (3) appointees from each of SGH and
              pSiOnco. The initial Members of the Joint Research Committee shall
              be as follows:

              SGH MEMBER                         PSIONCO  MEMBER

              Pierce Chow                        Leigh Canham

              Kai Zhang                          Steve Connor

              Robert Tech Hin                    Roghieh Safie

<PAGE>
                                      -12-

       4.3.2  In addition to the three SGH Members SGH may invite an employee or
              representative  of SGH (an  "INVITEE")  to  meetings  of the Joint
              Research  Committee if in SGH's  opinion the  attendance  of a SGH
              employee or representative is desirable in relation to one or more
              items on the agenda of the relevant  meeting or for the purpose of
              properly advising SGH in relation to matters under this Agreement.
              Prior to any such meeting SGH shall  inform  pSiOnco in writing of
              the SGH employee or representative who will be in attendance.

       4.3.3  In addition to the three  pSiOnco  Members,  pSiOnco may invite an
              additional employee or representative of pSiOnco (an "INVITEE") to
              meetings of the Joint Research  Committee if in pSiOnco's  opinion
              the  attendance  of such  pSiOnco  employee or  representative  is
              desirable  in  relation  to one or more items on the agenda of the
              relevant  meeting or for the  purpose of  properly  advising it in
              relation  to  matters  under  this  Agreement.  Prior  to any such
              meeting  pSiOnco  shall  inform  SGH in  writing  of  the  pSiOnco
              employee or representative who will be in attendance.

       4.3.4  Each of SGH and  pSiOnco  shall be  entitled  to remove any Member
              appointed  by it and to  appoint  any  person  to  fill a  vacancy
              arising from the removal or retirement of such Member.  Each Party
              shall give the others prior written notice of any proposed changes
              in the identity of their Members.

       4.3.5  The Parties  shall use all  reasonable  endeavours  to ensure that
              their  appointed  Members  and/or  Invitees  are  of  a  level  of
              expertise  and seniority to deal with the issues that may arise in
              connection with the Research Programme.

       4.3.6  The Joint Research  Committee  shall meet forthwith  following the
              Commencement  Date and thereafter  shall hold regular  meetings at
              intervals  of not more than four (4) months and at any time during
              normal  business  hours on any  Business  Day upon the  request of
              either SGH or pSiOnco.

<PAGE>
                                      -13-

       4.3.7  The venue for all meetings shall be in Singapore, unless otherwise
              agreed,  in which case (where the  meeting  does not take place in
              Singapore at the request of pSiOnco) pSiOnco shall bear all travel
              and subsistence costs incurred by SGH's Members in connection with
              their  attending the meeting in question.  A Member or Invitee may
              attend by  telephone  or video  conference  provided  that all the
              Members present can hear all parts of the proceedings.

       4.3.8  At least fourteen (14) days' written notice of each meeting of the
              Joint  Research  Committee  shall be given to each  Member  by the
              Party convening the meeting.

       4.3.9  The quorum for meetings of the Joint Research  Committee  shall be
              four (4) Members  provided  at least two (2) Members  from each of
              SGH and pSiOnco are  present.  Members may be  represented  at any
              meeting  by  another  Member  designated  in writing by the absent
              Member.  Members  attending by  telephone  or by video  conference
              shall for the avoidance of doubt count in the quorum.

       4.3.10 The  chairman of the Joint  Research  Committee  (who shall be the
              research  director of the Research Group or in his absence another
              member of the Joint Research  Committee)  shall be responsible for
              the  preparation  of the  minutes  of each  meeting  of the  Joint
              Research Committee. A copy of the minutes of each meeting shall be
              sent to each  of the  Members  within  fourteen  (14)  days of the
              meeting  which they  record.  The minutes  for a meeting  shall be
              approved by the Joint Research Committee at the next meeting.

       4.3.11 The  Chairman  of  the  Joint  Research  Committee  or  his or her
              designate shall prepare quarterly reports during the Research Term
              summarising  in  reasonable  detail the  results  of the  Research
              Programme  during the  preceding  quarter.  Copies of such reports
              shall  be sent  to the  Parties  within  30 days of the end of the
              quarter to which they relate.

<PAGE>
                                      -14-

5.     RESEARCH FUNDING

       5.1    As a  contribution  to SGH's costs for  carrying  out its allotted
              tasks under the Research Programme, pSiOnco shall make payments to
              SGH in  accordance  with  the  Research  Plan  costs  outlined  in
              Schedule 1.

       5.2    All payments  shall be made by pSiOnco in  Singapore  dollars on a
              quarterly  basis upon  submission  of a valid invoice by SGH. Such
              payments shall be made directly to SGH as directed by SGH.

       5.3    SGH shall apply the payments  received  from  pSiOnco  pursuant to
              Clause 5.1  exclusively  for the sole  purpose of carrying out the
              Research Programme.

6.     ACADEMIC COLLABORATIONS

       6.1    The  Parties  acknowledge  that  it  may  be  desirable  to  forge
              collaborative  links with Third Party  academic  groups to support
              the  Research  Programme.  In the  event  that  SGH  desires  such
              collaboration,  the  opportunity  in question shall be referred to
              the Board for approval of any such  collaboration.  pSiOnco  shall
              not unreasonably  hinder the establishment of such links where the
              Third Party in question is willing to enter into the collaboration
              on  reasonable  terms and where the  results of such  Third  Party
              collaboration will be available to pSiOnco within the framework of
              the Research  Programme.  SGH shall not, without the prior written
              consent of pSiOnco,  encumber any Programme  Intellectual Property
              in any such academic collaboration.

       6.2    In the event that pSiOnco desires a collaboration  between SGH and
              a Third Party,  the  opportunity  in question shall be referred to
              the Chief Executive of SGH for written  approval and SGH shall not
              unreasonably  hinder the  establishment  of such  links  where the
              Third Party in question is willing to enter into the collaboration
              on  reasonable  terms and where the  results of such  Third  Party
              collaboration will be available to pSiOnco within the framework of
              the Research  Programme.  SGH shall not be under any obligation to
              accept such a  collaboration  which by way of such a collaboration
              with a Third  Party  significantly  alters  SGH's  obligations  to
              pSiOnco as detailed in this Agreement.

<PAGE>
                                      -15-

       6.3    Each Party shall  ensure that no  Documents  are  published by any
              Third Party collaborator unless in accordance with Clause 11.

7.     OWNERSHIP AND MANAGEMENT OF INTELLECTUAL PROPERTY

       7.1    SGH and SGHT hereby assign by way of present and future assignment
              with full title guarantee and free from charges,  liens, mortgages
              or other  encumbrances of any kind to hold unto pSiOnco absolutely
              all their interests in and to any Programme  Intellectual Property
              and the full and exclusive benefits thereof and rights, privileges
              and advantages associated with them including:

              7.1.1  the full  right to apply for and  obtain  patents  or other
                     forms of  protection  in  respect of all or any part of the
                     Programme Intellectual Property throughout the world;

              7.1.2  the right to claim  priority  from the  patent  application
                     included  with  any  programme   Patents  under  the  Paris
                     Convention (as amended) when making such applications;

              7.1.3  the   right   to   file   divisional,    continuation   and
                     continuation-in-part   applications  in  its  own  name  in
                     respect  of  subject  matter  described  in  the  Programme
                     Patents; and

              7.1.4  the right to recover,  and take all such proceedings as may
                     be necessary for the recovery of, damages or other forms of
                     relief  in  respect  of  all  infringements  of  rights  in
                     Programme   Intellectual   Property  or  any  other  rights
                     assigned under this  Agreement  matters taking place before
                     or after the Commencement Date.

       7.2    SGH and SGHT  hereby  agree to do or  procure to be done all other
              acts and to execute  and deliver all such  further  documents  and
              instruments  as shall  be  required  to give  full  effect  to the
              assignment  under  Clause 7.1 or the  recording by pSiOnco of such
              assignment  including  by signing  any  documents  required by any
              national patent office or other equivalent registry.

<PAGE>
                                      -16-

       7.3    The  prosecution,  maintenance,  defence  and  enforcement  of the
              Programme  Intellectual  Property shall be the  responsibility  of
              pSiOnco  save that  pSiOnco  shall give copies of all  significant
              documents  relating  to the same to SGH and SGHT in order that SGH
              and SGHT may keep  records of all relevant  events  related to the
              Programme Intellectual Property.

8      CONSIDERATION

8.1    Subject  to  the  provisions  of the  Share  Subscription  Agreement,  on
       achievement  of a milestone (as detailed in Clauses 8.1.1 to 8.1.3 below)
       within the Research Term plus six months, SGHT together with BRV shall be
       entitled  to  subscribe  for the  further  number of  ordinary  shares in
       pSiOnco  set out in  Clauses  8.1.1 to 8.1.3  below  (in the ratio of two
       thirds to SGHT and one third to BRV) [***]:

       8.1.1  [***] on completion of pre-clinical studies leading to approval by
              the Ethics  Committee or any other  appropriate  committee for the
              first trial in humans;

       8.1.2  [***] on completion of the first clinical trial to test for safety
              in a human; and

       8.1.3  [***] on completion of the first clinical trial to demonstrate for
              efficacy in a human.

8.2    The  subscription  price per share for such  further  tranches  of shares
       shall be [***].

8.3    Such shares issued in accordance  with this Clause 8 will be held subject
       to and in accordance with the Share Subscription  Agreement and pSiOnco's
       articles of association.

8.4    For the  avoidance  of  doubt  SGHT  and BRV  shall  not be  entitled  to
       subscribe for any shares under this Clause 8 in respect of the successful
       achievement of (a) particular  milestone(s) if such milestone(s) have not
       been  achieved  before  the expiry of the  Research  Term plus six months
       unless otherwise agreed by pSiOnco.

8.5    The  number  of  shares  referred  to in this  Clause 8 and the par value
       referred  to in  Clause  8.2 shall be  adjusted  to take  account  of any
       sub-division or consolidation of the ordinary share capital of pSiOnco.

<PAGE>
                                      -17-

9.     WARRANTIES AND LIABILITY

       9.1    Each Party represents and warrants to the other Parties that:

              9.1.1  it has legal power,  authority and right to enter into this
                     Agreement and to perform its respective  obligations and to
                     grant and/or assign the rights hereunder;

              9.1.2  it  is  not  at  the  Commencement  Date  a  party  to  any
                     agreement,  arrangement  or  understanding  with any  Third
                     Party which in any material way prevents it from fulfilling
                     any of its material obligations hereunder;

              9.1.3  this  Agreement  has been duly  authorised,  executed,  and
                     delivered  by  that  Party  and is a  valid,  binding,  and
                     legally enforceable obligation of that Party;

              9.1.4  no consent, approval,  authorisation, or order of any court
                     or  governmental   agency  or  body  is  required  for  the
                     consummation  of  the  transactions  contemplated  by  this
                     Agreement; and

              9.1.5  all Intellectual  Property  generated by the Research Group
                     during  the  course  of the  Research  Programme  will vest
                     automatically  by  operation  of  law  or  pursuant  to the
                     relevant  Research Group member's contract of employment in
                     the Party employing the relevant Research Group member.

       9.2    SGH warrants that the Research  Group will not during the Research
              Term  collaborate  in the Field with any  commercial  Third  Party
              without the prior written consent of pSiOnco.

       9.3    Save as  provided  in  Clauses  9.1 and 9.2,  no Party  gives  any
              representation or warranty to any other Party that the performance
              of this  Agreement  will not  result  in the  infringement  of any
              rights, including Intellectual Property, vested in a Third Party.

       9.4    No Party  shall be liable  to any other  Party,  or  members  of a
              Party's  Group or that Party's  sub-licensees  in contract,  tort,
              negligence,  breach of statutory  duty or otherwise  for any loss,
              damage,  cost or expense of an  indirect or  consequential  nature
              (including  any economic loss or other loss of turnover,  profits,
              business or goodwill)  arising out of or in  connection  with this
              Agreement or the subject matter of this  Agreement  whether or not
              that Party had been advised of the possibility of such loss.

<PAGE>
                                      -18-

       9.5    Nothing in this Agreement  shall be construed as a  representation
              made or  warranty  given by any Party that any  patent  will issue
              based upon any pending patent application  included in the pSiOnco
              Patents or the Programme  Intellectual  Property,  that any patent
              included  in the  pSiOnco  Patents or the  Programme  Intellectual
              Property  which  issues  will be  valid,  or  that  the use of any
              pSiOnco Patents or the Programme  Intellectual Property or pSiOnco
              Know How will not infringe the patent or proprietary rights of any
              other  person.  Furthermore,  pSiOnco makes no  representation  or
              warranty, express or implied, with respect to the pSiOnco Patents,
              pSiOnco Know How or the Programme Intellectual Property, including
              without limitation, any warranty of merchantability or fitness for
              a particular purpose.

       9.6    Except as provided in this Agreement all Materials provided by any
              Party and data  generated by or on behalf of that Party under this
              Agreement  are provided  without any  representation  or warranty,
              express or  implied,  including  without  limitation  any  implied
              warranty of  merchantability or fitness for any particular purpose
              or any warranty that the use of the materials will not infringe or
              violate  any  patent  or other  proprietary  rights  of any  other
              person.

       9.7    Nothing in this Agreement  shall be construed as a  representation
              made or  warranty  given  by any  Party to fund  any  research  or
              development other than as set out in the Research Programme.

10.    CONFIDENTIALITY

       10.1   Each  Party  undertakes  and agrees not at any time for any reason
              whatsoever  to  disclose  or permit to be  disclosed  to any Third
              Party or otherwise make use of or permit to be made use of (except
              as  expressly  permitted  pursuant to this  Agreement),  any trade
              secrets or confidential information relating inter alia to another
              Party's technology  (including the Intellectual  Property licensed
              by either party pursuant to this Agreement to the extent that such
              Intellectual  Property  has not been  published)  or the  business
              affairs  or  finances  of  another  Party or a member  of  another
              Party's  Group,   sub-licensee   or  of  any  suppliers,   agents,
              distributors  or  customers  of another  Party (the  "CONFIDENTIAL
              INFORMATION")  which  come into its  possession  pursuant  to this
              Agreement.

<PAGE>
                                      -19-

       10.2   The  Parties  shall  ensure  that  only  those of their  officers,
              employees,  agents and consultants who are directly concerned with
              the carrying out of this Agreement and who have a need to know are
              given access to  Confidential  Information and that those who have
              access  to the  Confidential  Information  of  another  Party  are
              informed of its secret and confidential nature.

       10.3   Subject  to the  provisions  of  Clause  13,  the  obligations  of
              confidence  referred  to in this Clause 10 shall not extend to any
              Confidential Information which:

              10.3.1 is at  the  time  of  disclosure,  or  thereafter  becomes,
                     generally  available to the public otherwise than by reason
                     of a breach by the  recipient  Party of the  provisions  of
                     this Clause 10; or

              10.3.2 is known to the  recipient  Party  without  obligations  of
                     confidence  prior to its receipt from another Party, as can
                     be shown by written record; or

              10.3.3 is  subsequently  disclosed to the recipient  Party without
                     obligations  of  confidence  by another party owing no such
                     obligations in respect thereof; or

              10.3.4 is required to be  disclosed by any  applicable  law or any
                     Competent  Authority  to which a Party is from time to time
                     subject; or

              10.3.5 is  independently  developed by a person or persons with no
                     access  to  the  Confidential  Information  disclosed  by a
                     Party, as demonstrated by written records.

       10.4   The  obligations  of each Party under this Clause 10 shall survive
              until the  expiration  of five (5) years after the  expiration  or
              termination for whatever reason of this Agreement.

<PAGE>
                                      -20-

11.    PUBLICATIONS

       11.1   The members of the Research Group shall be entitled to publish the
              results of the Research  Programme provided that the provisions of
              this Clause 11 have been complied with.  The following  provisions
              shall  also apply in the case of article  abstracts  and  research
              presentations.

       11.2   A copy of any  manuscript  which a member  of the  Research  Group
              proposes to submit for publication and which contains or refers to
              results from the Research  Programme shall be sent to the Chairman
              of the Joint  Research  Committee  ( as defined in clause  4.3.10)
              prior to its submission for publication. The Chairman of the Joint
              Research  Committee  shall,   forthwith  on  receipt  of  a  draft
              manuscript,  send a copy to each of the other Members of the Joint
              Research  Committee and shall,  at the same time convene a meeting
              of the Joint Research  Committee  within  forty-five  (45) days of
              receipt of the  manuscript.  If this  meeting  does not take place
              within  forty-five  (45) days of the receipt of the  manuscript by
              the Chairman of the Joint  Research  Committee,  the member of the
              Research  Group  shall be  entitled  to  submit  the  results  for
              publication.  At the meeting the Joint  Research  Committee  shall
              decide  whether any delay in the  publication of the manuscript is
              necessary  or  desirable  for  the   protection  of  the  relevant
              Programme  Intellectual  Property.  At the same  meeting  it shall
              decide  whether  an  application  for a patent  should be filed in
              respect  of the  relevant  results.  If it  decides  that  such an
              application  should be filed pSiOnco shall be responsible for such
              a filing  pursuant to Clause 7. If it decides that a delay for the
              purpose of filing  patent  protection  is necessary it may require
              the  delay  of the  submission  for  publication  of the  relevant
              results  for up to a period of not more than  sixty (60) days from
              the date of the meeting of the Joint Research Committee at which a
              delay  was  requested  or  until  the  date on  which  the  patent
              application in question is filed,  whichever is shorter. Any delay
              beyond the said sixty (60) days may only be  required on the prior
              written agreement of both pSiOnco and SGH.

       11.3   Notwithstanding  the  confidentiality  obligations  assumed by SGH
              hereunder,  pSiOnco acknowledges the importance of publications to
              the academic standing of SGH. In the light of this,  pSiOnco shall
              use all reasonable  efforts to facilitate early publication of the
              results of the Research Programme.

<PAGE>
                                      -21-

12.    TERM AND TERMINATION

       12.1   This Agreement shall come into effect on the Commencement Date and
              shall expire at the end of the Research Term or on  termination or
              expiry  of  the  Patent  and  Know-how  Licence  whichever  is the
              earlier.

       12.2   Either  SGH and SGHT on the one hand or  pSiOnco on the other hand
              (the  "TERMINATING  PARTY") shall have the right to terminate this
              Agreement  forthwith  upon giving written notice of termination to
              pSiOnco  on the one hand or SGH and SGHT on the other  hand as the
              case may be (the "DEFAULTING  PARTY"),  upon the occurrence of any
              of the following events at any time during this Agreement:

              12.2.1 the  Defaulting  Party  commits a  material  breach of this
                     Agreement  which in the case of a breach  capable of remedy
                     shall not have been  remedied  within  thirty (30) Business
                     Days  of the  receipt  by it of a  notice  identifying  the
                     breach and requiring its remedy;

              12.2.2 the Defaulting Party for a period of longer than sixty (60)
                     Business  Days  suspends  payment of its debts or otherwise
                     ceases or  threatens  to cease to carry on its  business or
                     becomes bankrupt or insolvent (including without limitation
                     being deemed to be unable to pay its debts);

              12.2.3 a proposal is made or a nominee or  supervisor is appointed
                     for a  composition  in  satisfaction  of the  debts  of the
                     Defaulting Party or a scheme or arrangement of its affairs,
                     or the  Defaulting  Party  enters into any  composition  or
                     arrangement   for  the   benefit  of  its   creditors,   or
                     proceedings  are  commenced  in relation to the  Defaulting
                     Party under any law,  regulation  or procedure  relating to
                     the  re-construction  or  re-adjustment of debts (including
                     where a petition is filed or proceeding  commenced  seeking
                     any    reorganisation,    arrangement,    composition    or
                     re-adjustment under any applicable bankruptcy,  insolvency,
                     moratorium,  reorganisation  or other similar law affecting
                     creditor's  rights or where the  Defaulting  Party consents
                     to, or acquiesces in, the filing of such a petition); or

<PAGE>
                                      -22-

              12.2.4 the  Defaulting  Party  takes  any  action,  or  any  legal
                     proceedings  are  started or other  steps  taken by a Third
                     Party, with a view to:

                     (i)    the  winding  up or  dissolution  of the  Defaulting
                            Party  (other  than  for  the  reconstruction  of  a
                            solvent  company  for  any  purpose,  including  the
                            inclusion  of any part of the share  capital  of the
                            Defaulting  Party  on  a  recognised   public  Stock
                            Exchange), or

                     (ii)   the appointment of a liquidator,  trustee, receiver,
                            administrative   receiver,   receiver  and  manager,
                            interim receiver custodian,  sequestrator or similar
                            officer  of  the   Defaulting   Party   against  the
                            Defaulting Party or a substantial part of the assets
                            of the Defaulting Party;

                     or anything  analogous to any of the foregoing occurs under
                     the laws of any country.

       12.3   pSiOnco shall be entitled to terminate this Agreement  immediately
              by  notice  in  writing  to SGH or  SGHT  if  either  SGH or  SGHT
              challenges the validity of the pSiOnco Patents or any of them.

13.    CONSEQUENCES OF TERMINATION

       13.1   Upon expiry or termination of this Agreement:

              13.1.1 the licence right granted by pSiOnco pursuant to Clause 2.2
                     shall terminate;

              13.1.2 pSiOnco  shall pay to SGH within sixty (60)  Business  Days
                     all sums due to SGH  hereunder  which have accrued prior to
                     the date of  termination  unless  such  termination  is the
                     result of a  material  breach of this  Agreement  by SGH or
                     SGHT;

       13.2   If pSiOnco terminates this Agreement for any reason other than for
              the  default  of SGH or SGHT it shall pay to SGH within 30 days of
              such termination all sums which would have been paid to SGH as set
              out  in  Schedule  1 and  which  relate  to  costs  that  SGH  can
              demonstrate  are  legally   committed  that  cannot  otherwise  be
              utilised by SGH elsewhere by SGH for the remainder of the Research
              Term. For the avoidance of doubt,  SGH shall have an obligation to
              mitigate to the extent  possible  the level of any such  committed
              costs.  Where committed  costs cannot  otherwise by re-utilised by
              SGH,  the  Parties  will  negotiate  in good faith to find ways in
              which the Parties can  constructively use any such committed costs
              to the benefit of all the Parties.

<PAGE>
                                      -23-

       13.3   Termination or expiry of this Agreement for whatever  reason shall
              not affect the accrued  rights of the  Parties  arising in any way
              out of this  Agreement as at the date of termination or expiry and
              in particular but without  limitation the right to recover damages
              and interest,  and the provisions of Clauses 2.1, 7, 8, 9, 10, 11,
              15, 16,  17,  20, 21 23, 24 and 25 shall  remain in full force and
              effect.

14.    CHANGE OF RESEARCH PROGRAMME

       14.1   Either SGH or pSiOnco may propose any reasonable  modification  to
              any  element of the  Research  Programme  in  accordance  with the
              Change of Research Programme Procedure (the "PROPOSER") by written
              notice to the other (the "PROPOSEES") specifying in as much detail
              as is  reasonably  practicable  the  nature of the  Change and the
              additional work or materials required.

       14.2   As soon  as  reasonably  practicable  thereafter  and in any  case
              within 30 days of sending  or  receipt of a request  for a change,
              the Proposer will provide a brief written  proposal  including but
              not limited to:

              14.2.1 details of the proposed Change;

              14.2.2 any   difference  in  the  costs  set  out  in  Schedule  2
                     necessitated as a result of the proposed Change;

              14.2.3 a  timetable  for the  implementation,  together  with  any
                     proposals for acceptance, of the proposed Change; and

              14.2.4 details  of the  likely  impact,  if any,  of the  proposed
                     Change  on  any  existing   services  being   performed  in
                     accordance with the Research Programme.

<PAGE>
                                      -24-

       14.3   The Proposee will,  unless otherwise  agreed,  review the proposal
              within 15 Business Days after its receipt and will either:

              14.3.1 accept  the  proposed   Change  and  vary  this   Agreement
                     accordingly and SGH will implement the Change in accordance
                     with agreed timetable; or

              14.3.2 reject the proposed Change; or

              14.3.3 refer the  proposed  Change to an  alternative  appropriate
                     forum for discussion.

       14.4   If the Proposee rejects the proposed  Change,  it shall provide in
              writing to the  Proposer  the reasons for  rejecting  the proposed
              Change and the Proposer shall have the  opportunity,  should it so
              wish, to provide an amended Change proposal for the other Party to
              review in  accordance  with Clause  14.3.  Neither SGH nor pSiOnco
              shall unreasonably withhold its agreement to any proposed Change.

       14.5   SGH will not  commence  work in  connection  with  any  Change  or
              addition to the scope of the services  provided under the Research
              Programme  until the  relevant  Change is agreed by the parties in
              writing in accordance with this Clause 14.

15.    WAIVER

       No Party  shall be deemed to have  waived any of its  rights or  remedies
       conferred  by this  Agreement  unless the  waiver is made in writing  and
       signed by a duly authorised  representative of that Party. In particular,
       no delay or failure of any Party in  exercising  or enforcing  any of its
       rights or remedies  conferred by this Agreement shall operate as a waiver
       of those  rights or remedies or so as to preclude or impair the  exercise
       or enforcement of those rights or remedies nor shall any partial exercise
       or enforcement of any right or remedy by any Party preclude or impair any
       other exercise or enforcement of that right or remedy by that Party.

16.    ENTIRE AGREEMENT/VARIATIONS

       16.1   This Agreement and the Share  Subscription  Agreement  constitutes
              the entire  agreement  and  understanding  between  the Parties in
              relation to the subject  matter of this  Agreement and  supersedes
              all   prior   oral  or   written   understandings,   arrangements,
              representations or agreements between them relating to the subject
              matter of this  Agreement.  No director,  employee or agent of any
              Party is  authorised  to make any  representation  or  warranty to
              another  Party not  contained  in this  Agreement,  and each Party
              acknowledges  that it has not  relied on any such oral or  written
              representations or warranties.

<PAGE>
                                      -25-

       16.2   No  variation,  amendments,  modification  or  supplement  to this
              Agreement  shall be valid  unless  made in writing in the  English
              language and signed by a duly  authorised  representative  of each
              Party.

17.    NOTICES

       17.1   Any  notice to be given  pursuant  to this  Agreement  shall be in
              writing in the English  language  and shall be  delivered by hand,
              sent by  registered or recorded  delivery  airmail post or sent by
              facsimile confirmed by registered or recorded delivery post to the
              address or facsimile number of the recipient set out below or such
              other address or facsimile number as a Party may from time to time
              designate by written notice to the other Parties.

            ADDRESS OF SGH

            for the attention of:     Chief Executive Officer
                                      Executive Office
                                      Block 7, Level 1
                                      Outram Road
                                      Singapore
                                      169608

            fax number:               (65) 6222 1720

            ADDRESS OF PSIONCO

            for the attention of:     Dr. Roger Aston/Mr. Sunny Wong
                                      c/o Wong Tan & Molly Lim
                                      80 Robinson Road 17-02
                                      Singapore 068898

            fax number:               (65) 6222 8001

<PAGE>
                                      -26-

            ADDRESS OF SGHT

            for the attention of:     c/o Singapore General Hospital Pte. Ltd.
                                      Chief Executive Officer
                                      Executive Office
                                      Block 7, Level 1
                                      Outram Road
                                      Singapore
                                      169608

            fax number:               (65) 6222 1720

       17.2   Any notice  given  pursuant  to this  Clause 17 shall be deemed to
              have been received:

              17.2.1 in the case of delivery by hand, when delivered; or

              17.2.2 in the case of sending by post:

                     (i)    where posted in the country of the addressee, on the
                            third Business Day following the day of posting; and

                     (ii)   where  posted in any other  country,  on the seventh
                            Business Day following the day of posting; or

              17.2.3 in  the  case  of  facsimile,  on  acknowledgement  by  the
                     recipient  facsimile  receiving equipment on a Business Day
                     if the acknowledgement  occurs before 1700 hours local time
                     of the  recipient  and in any other  case on the  following
                     Business Day.

18.    ASSIGNMENT

       18.1   Save as  otherwise  provided  in this  Agreement,  no Party  shall
              without the prior written consent of the other Parties, assign the
              benefit  and/or burden of this Agreement nor  sub-contract  any of
              its  obligations  hereunder  unless  otherwise  permitted  by  the
              written agreement of all Parties.

<PAGE>
                                      -27-

19.    FORCE MAJEURE

       19.1   If a Party (the "Non-Performing Party") is unable to carry out any
              of its obligations  under this Agreement due to Force Majeure this
              Agreement  shall remain in effect but the  Non-Performing  Party's
              relevant   obligations  under  this  Agreement  and  the  relevant
              obligations  of the other Parties ("the Innocent  Parties")  under
              this  Agreement  shall  be  suspended  for a  period  equal to the
              duration of the circumstance of Force Majeure provided that:

              19.1.1 the  suspension of  performance is of no greater scope than
                     is required by the Force Majeure;

              19.1.2 the Non-Performing  Party gives the Innocent Parties prompt
                     notice   describing  the  circumstance  of  Force  Majeure,
                     including  the nature of the  occurrence  and its  expected
                     duration,  and continues to furnish  regular reports during
                     the period of Force Majeure;

              19.1.3 the  Non-Performing  Party uses all  reasonable  efforts to
                     remedy its inability to perform and to mitigate the effects
                     of the circumstance of Force Majeure; and

              19.1.4 as soon as  practicable  after the event which  constitutes
                     Force  Majeure  the  Parties  shall  discuss  how  best  to
                     continue their  operations as far as possible in accordance
                     with this Agreement.

       19.2   If Force Majeure is continuing at the expiry of 3 months either of
              the Innocent  Parties may give thirty (30)  Business  Days written
              notice to terminate this Agreement to the Non-Performing Party and
              termination  shall occur if the Force Majeure is continuing at the
              end of that thirty (30) Business Day notice period.

       19.3   SGHT and SGH shall not be  entitled  to claim that  Force  Majeure
              applies as a result of the  actions,  decrees or  otherwise of any
              Singaporean  Government  body  if  the  primary  purpose  of  such
              actions,  decrees or  otherwise  was to enable  SGHT and/or SGH to
              claim Force Majeure.

20.    ARBITRATION

       20.1   Any question, difference or dispute which may arise concerning the
              construction meaning or effect of this Agreement or concerning the
              rights  and  liabilities  of the  Parties  hereunder  or any other
              matter arising out of or in connection  with this Agreement  shall
              first be  submitted  to the  Chairman of the Board of Directors of
              pSiOnco, and the CEO of SGH for resolution, who may call on others
              to advise them as they see fit.

<PAGE>
                                      -28-

       20.2   If the  discussions  under  Clause 20.1 should fail to resolve the
              question,  difference or dispute  within ninety (90) Business Days
              of commencement  of the discussions  under Clause 20.1 then any of
              the Parties to the dispute may refer the matter for  determination
              by arbitration at the Singapore  International  Arbitration Centre
              ("SIAC") and such submission  shall be a submission to arbitration
              in accordance  with the Rules of the SIAC as presently in force by
              which the  Parties in dispute  agree to be so bound.  The place of
              arbitration  shall  be  Singapore  and the  arbitration  shall  be
              conducted wholly in the English language.

21.    SEVERANCE OF TERMS

       21.1   If the whole or any part of this  Agreement  is or  becomes  or is
              declared illegal, invalid or unenforceable in any jurisdiction for
              any  reason  (including  both by reason of the  provisions  of any
              legislation and also by reason of any court or Competent Authority
              which  either  has   jurisdiction   over  this  Agreement  or  has
              jurisdiction over any of the Parties):

              21.1.1 in   the   case   of   the   illegality,    invalidity   or
                     un-enforceability  of the whole of this  Agreement it shall
                     terminate only in relation to the jurisdiction in question;
                     or

              21.1.2 in   the   case   of   the   illegality,    invalidity   or
                     un-enforceability of part of this Agreement that part shall
                     be  severed  from this  Agreement  in the  jurisdiction  in
                     question    and    that    illegality,     invalidity    or
                     un-enforceability shall not in any way whatsoever prejudice
                     or affect the remaining parts of this Agreement which shall
                     continue in full force and effect.

       21.2   If in the reasonable opinion of any Party any severance under this
              Clause  21  materially   affects  the  commercial  basis  of  this
              Agreement,  the Parties  shall  discuss,  in good  faith,  ways to
              eliminate the material effect.

<PAGE>
                                      -29-

22.    THIS AGREEMENT NOT TO CONSTITUTE A PARTNERSHIP

       22.1   None of the  provisions  of this  Agreement  shall  be  deemed  to
              constitute  a  partnership  between  the  Parties  and none of the
              Parties  shall  have any  authority  to bind the others in any way
              except as provided in this Agreement.

23.    PUBLIC STATEMENTS

       23.1   Except as provided  in Clause  23.2,  no Party  will,  without the
              prior written consent of each other Party:

              23.1.1 use in advertising,  publicly or otherwise, any trade-name,
                     personal  name,  trademark,  trade  device,  service  mark,
                     symbol,  or any  abbreviation,  contraction  or  simulation
                     thereof, owned by another Party; or

              23.1.2 represent,  either directly or indirectly, that any product
                     or service of another  Party is a product or service of the
                     representing Party or that it is made in accordance with or
                     utilises the information or documents of the another Party.

       23.2   The restrictions in Clause 22.1 shall not apply to the following:

              23.2.1 a press release,  in a form agreed to in writing by all the
                     Parties, publicly announcing this Agreement; or

              23.2.2 use as  required  by  any  applicable  law or  governmental
                     regulation.

24.    COSTS

       24.1   Each Party  shall bear its own legal  costs,  legal fees and other
              expenses  incurred  in  the  preparation  and  execution  of  this
              Agreement.

25.    GOVERNING LAW AND JURISDICTION

       25.1   The validity, construction and performance of this Agreement shall
              be governed by the laws of Singapore  and subject to the exclusive
              jurisdiction of the courts of the Republic of Singapore.

<PAGE>
                                      -30-

                                   SCHEDULE 1

                              OUTLINE RESEARCH PLAN

                                     Part 1
                         COLLABORATIVE ONCOLOGY RESEARCH

                                    Between:

PSIONCOLOGY  PTE.  LTD AND  SINGAPORE  GENERAL  HOSPITAL,  DEPT OF  EXPERIMENTAL
SURGERY

Dr. Pierce Chow
Director, Dept of Experimental Surgery
Singapore General Hospital
Outram Road
Singapore 169608

SUMMARY OF RESEARCH AIMS AND METHODOLOGY

pSiOnco and SGH wish to carry out proof-of-principle research to verify the
above hypotheses.

Established commercial tumour cell lines will be implanted into either nude or
skid mice and allowed to develop to a suitable size. Barbs made from BioSilicon
(TM) and suitably impregnated with chemotherapeutic agents or a radiation source
as appropriate are then introduced into the tumour using a novel device (to be
developed by pSiMedica). The tumours are monitored and compared with those in
control groups.

RESEARCH SITE AND FACILITIES

The above animal research will be carried out in the animal laboratory of the
Dept of Experimental Surgery, Singapore General Hospital. Researchers from the
Dept. together with other technical staff will procure the necessary animals,
which will be housed in the laminar flow facility in the laboratory designed for
nude/skid animals. The same researchers will be responsible for introducing the
tumour lines into the animals and subsequently introducing the BioSilicon (TM)
barbs into the tumours and monitoring the progress of the tumours. Tumour
regression will be documented both macroscopically and by histology. HPLC
facilities in the laboratory will be used for monitoring of serum levels of
drugs.

pSiOnco will be responsible for preparing impregnated BioSilicon (TM) barbs and
developing a novel device for introducing the barbs into biological tissues. The
barbs and device will be shipped to the Dept of Experimental Surgery for the
purpose of the research.

<PAGE>
                                      -31-

CELL LINES AND CHEMOTHERAPEUTIC AGENTS

The following cell lines will be used. These are lines that staff of the Dept of
Experimental Surgery are familiar with and have direct experience of.

Cell lines:       HepG2, AGS, HTB-88, 224-CCL

The following chemotherapeutic agents are suitable for the above cell lines and
will be used. Drugs: Adriamycin, chlorambucil, gemcitabine, actinomycin D,
cisplatin The above are by no means exhaustive and if some of the suggested
drugs are not suitable for BioSilicon (TM) for technical reasons, others can be
substituted.

RADIATION SOURCES

It is proposed that 32P, a beta emitter with a maximum energy of 1.71MeV (range
800 microns in photographic emulsion) and a half life of 14.3 days be used as a
radiation source. This radionuclide can be created throughout the Si skeleton
itself via the well-developed Si industry process of "neutron transmutation
doping"

OUTLINE OF RESEARCH PROTOCOL AND TIME-FRAME

Each of the 4 cell-lines is introduced into equal groups of skid and nude mice
giving a final tally of:

------------------- -------- --------------------- --------------------
    CELL-LINE                   BRACHYTHERAPY         CHEMOTHERAPY
------------------- -------- --------------------- --------------------
HepG2               Nude              20                   20
------------------- -------- --------------------- --------------------
                    Skid              20                   20
------------------- -------- --------------------- --------------------
AGS                 Nude              20                   20
------------------- -------- --------------------- --------------------
                    Skid              20                   20
------------------- -------- --------------------- --------------------
HTB-88              Nude              20                   20
------------------- -------- --------------------- --------------------
                    Skid              20                   20
------------------- -------- --------------------- --------------------
224-CCL             Nude              20                   20
------------------- -------- --------------------- --------------------
                    Skid              20                   20
------------------- -------- --------------------- --------------------
Control             Nude              20                   20
------------------- -------- --------------------- --------------------
                    Skid              20                   20
------------------- -------- --------------------- --------------------
Total
------------------- -------- --------------------- --------------------

      1.    The cell lines are introduced  subcutaneously into the flanks of the
            animals under anesthesia and the growth monitored every 3 days.

      2.    At  between  3 - 5 weeks  (depending  on the  cell  lines)  once the
            tumours  have  developed  to a size when the  greatest  diameter  is
            between 2-3 cm,  appropriate  barbs are introduced  into the tumours
            under anesthesia after surgical reflection of the skin.

      3.    Further  progress  of the  tumour  is  monitored.  Animals  will  be
            sacrificed if the tumours  continue to progress and has grown by 50%
            of diameter size or more.

      4.    1 ml of blood will be collected  from the femoral vein of the animal
            treated  with  chemotherapy  when the  barbs are  introduced  and at
            sacrifice  or when the tumour has  regressed  to 20% of the original
            diameter.  Baseline and  subsequent  levels of the  chemotherapeutic
            agents will be determined by HPLC.

<PAGE>
                                      -32-

Endpoints

Primary end-point          Tumour regression

Secondary end-point        Survival of animals, drugs levels

References

      1.    Int J Oncol 1999 May;14(5):861-7.  GSH, GSH-related enzymes and GS-X
            pump in  relation  to  sensitivity  of  human  tumor  cell  lines to
            chlorambucil and adriamycin. Zhang K, Yang EB, Wong KP, Mack P.

      2.    Cancer Lett 2000 Feb 28;149(1-2):213-20. Glutathione-related factors
            are not  correlated  with  sensitivity  of  human  tumour  cells  to
            actinomycin D. Zhang K, Yang EB, Zhao YN, Wong KP, Mack P.

      3.    Int J Oncol 2000 Mar;16(3):599-610.  Transforming growth factor-beta
            and  response  to  anticancer  therapies  in human liver and gastric
            tumors  in vitro  and in vivo.  Liu P,  Menon  K,  Alvarez  E, Lu K,
            Teicher BA.

      4.    J Hepatol 1998  Mar;28(3):504-9.  Antitumor effect of the nucleoside
            analogs  2-chlorodeoxyadenosine and  2',2'-difluorodeoxycytidine  on
            human hepatoma HepG2 cells. Graziadei I, Kelly T, Schirmer M, Geisen
            FH, Vogel W, Konwalinka G.

      5.    Int  J  Mol  Med  1999  Aug;4(2):203-12.  Modulation  of  biological
            phenotypes  for  tumor  growth  and  metastasis  by  target-specific
            biological inhibitors in gastric cancer. Rha SY, Noh SH, Kim TS, Yoo
            NC, Roh JK, Min JS, Kim BS.

      6.    Invest  New  Drugs   1991   Feb;9(1):29-36.   Relationship   between
            glutathione  levels  and drug or  radiation  sensitivities  in human
            gastric  cancer  cell  lines in vitro.  Barranco  SC,  Weintraub  B,
            MacLean KK, Beasley EG, Jenkins VK, Townsend CM Jr.

      7.    Invest  New  Drugs  1990;8   Suppl   1:S9-18.   Schedule   dependent
            potentiation       of      antitumor       drug      effects      by
            alpha-difluoromethylornithine  in human gastric  carcinoma  cells in
            vitro.  Barranco SC,  Townsend CM Jr, Ho BY, Reumont KJ, Koester SK,
            Ford PJ.

      8.    Mol   Pharmacol   2001   Apr;59(4):837-43Modulation   of   cisplatin
            cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by
            regulation of glutathione-related  mechanisms. Zhang K, Chew M, Yang
            EB, Wong KP, Mack P.

<PAGE>
                                      -33-

                                   SCHEDULE 1

                                     PART 2

                             RESEARCH PLAN COSTINGS
COSTINGS FOR COLLABORATIVE RESEARCH:

                            COSTING AND WORK SCHEDULE
                           FOR COLLABORATIVE RESEARCH
                                     BETWEEN
                              PSI ONCOLOGY PTE LTD
                                       AND
                          DEPT OF EXPERIMENTAL SURGERY
                           SINGAPORE GENERAL HOSPITAL

The rates and work schedule below refer to the collaborative research
("research") previously discussed between PsiOnco and Dept of Experimental
Surgery (document "Outline Research Plan" 3rd Jan 2002, d) and are not
reflective of the general rates or cost of research carried out at the facility.
Quotes are in Singapore dollars and valid for 6 months.

1. ASSAY DEVELOPMENT AND QUANTIFICATION OF DRUGS IN TISSUE:

The Department of Experimental Surgery will undertake work to develop suitable
method(s) for quantification of drug levels in tissues (both tumour tissue and
surrounding non-tumour tissue). The methods developed may be novel and specific
for the purpose of the research.

COST OF DEVELOPMENT OF ASSAY

Cost of work done (inclusive of material)                       [***]

COST OF QUANTIFICATION OF DRUG LEVEL

*Cost per point quantification of drug level                    [***]

*It would be more equitable to the JV to cost on the basis of number of assays
rather than upfront because:

      1.    work  using   radioactive   therapeutic   source  does  not  require
            quantification of drug level

      2.    there will be animal  attrition

      3.    each good animal will require 10 tissue and 2 blood samples

<PAGE>
                                      -34-

We estimate at least 26 good animals per research "unit" of 40 animals (see
below) and hence projected cost will be 26 X [***]

2.    COST OF A SINGLE RESEARCH UNIT

The cost below refers to a single  research "unit" of 40 animals for a period of
[***].

1.    nude/skid mice                                    40 Nos. X [***]

2.    cell line preparation  (inclusive of media,
      flask,  serum, tubes etc.)                        40 Nos. X [***]

3.    Histology (excluding pathologist service)         40 Nos. X [***]

4.    Animal care [***]                                 30 X [***]

5.    Facility [***] Special collaborator's rate [***]  30 X [***]

                                   Total:                    [***]

3. WORK SCHEDULE

1.    Time from confirmation to start of research [***]

      1.    the assay will be developed in this period

      2.    animals will be ordered, quarantined, housed

      3.    it is assumed the pSiOnco has decided on the choice of agent(s)  and
            cell-line(s) at the time of confirmation

2.    Time from start of research to end of animal experiment [***]

3.    Time from end of animal experiments to final analysis and reports [***]

Notes: 1.    (1) and (3) may take less than [***]

       2.    as previously  discussed, work on the different  research units may
             start at different time-points - i.e. may be staggered

Robert Ng
Manager, Experimental Surgery

Pierce Chow
Director, Experimental Surgery

<PAGE>
                                      -35-

                                   SCHEDULE 1

                                     PART 3

PROPOSED RESEARCH WORK SCHEDULE WITH ESTIMATES COSTS FOR 2002/2003:

Research  project  structure  is based upon `the  Outline  Research  Plan' dated
January 2002 and shown in Schedule 1, Part 2.

Research  project costs at The Department of  Experimental  Surgery at Singapore
General Hospital are based upon `the costings and work schedule' dated 5th April
2002 and shown in Schedule 1, Part 3.

A summary of projected pre-clinical R&D is shown in Gant format in this Schedule
1, Part 4.

The projected costs for R&D are based upon the following assumptions:

Each `Research Unit' comprises approx 80 mice

The  programme  comprises  the  following  `research  grade  materials' to enter
pre-clinical studies:

      1.    32P silicon

      2.    Research grade cytotoxic drug A) loaded onto porous silicon

      3.    90Y porous silicon

      4.    Research grade cytotoxic drug B) loaded onto porous silicon

<TABLE>
<CAPTION>
-------------------------------------------------------------- --------------------- --------------------
                                                                       2002                 2003
-------------------------------------------------------------- --------------------- --------------------
<S>                                                            <C>                   <C>
32P Radiopharmaceutical powder                                 [***]                 [***]
-------------------------------------------------------------- --------------------- --------------------
Drug loaded powders, research grade Drug A                     [***]                 [***]
-------------------------------------------------------------- --------------------- --------------------
2nd Line: 90Y / Drug B) research grade powders                                       [***]
-------------------------------------------------------------- --------------------- --------------------
Technical staff (recruitment Q4 2002)                                                [***]
-------------------------------------------------------------- --------------------- --------------------

-------------------------------------------------------------- --------------------- --------------------
                                                       Total:  [***]                 [***]
-------------------------------------------------------------- --------------------- --------------------

-------------------------------------------------------------- --------------------- --------------------
</TABLE>

<PAGE>
                                      -36-

[***]

<PAGE>
                                      -37-

                                   SCHEDULE 2

                                PSIONCO KNOW-HOW

For the avoidance of doubt the following pSiMedica Know-how has been licensed by
pSiMedica  to pSiOnco  within the Field under a Patent and  Know-how  Licence of
even date of which this Agreement is subject.

To the extent that pSiOnco is reasonably able, pSiOnco will supply SGH with such
Know-How as is required by, SGH to use the pSiOnco  Materials and pSiOnco Patent
Rights.

<PAGE>
                                      -38-

                                   SCHEDULE 3

                                PSIONCO MATERIAL

For the avoidance of doubt the following  pSiMedica  Material have been licensed
by pSiMedica to pSiOnco within the Field under a Patent and Know-how  Licence of
even date of which this Agreement is subject.

Biocompatible Silicon (BioSilicon (TM)) and any other articles which pSiOnco may
furnish to SGH from time to time  which may fall under the scope of the  pSiOnco
Patent Rights.

<PAGE>
                                      -39-

                                   SCHEDULE 4

                              PSIONCO PATENT RIGHTS

For the avoidance of doubt the following pSiMedica Patents have been licensed by
pSiMedica  to pSiOnco  within the Field under a Patent and  Know-how  Licence of
even date of which this Agreement is subject.

PSIMEDICA  PATENTS

PATENTS 1-3 PUBLISHED ; INFO IN PUBLIC DOMAIN

1.       BIOMATERIAL:  GB 9801317.0, WO 97/06101, FILED 3RD AUGUST 1995.

         TOPIC AREAS:      in-vitro tests of porous and poly Si
                           demonstrating bioactivity and biodegradability in
                           simulated human plasma & effects of electrical bias

         CLAIMS:           bioactive silicon, resorbable silicon, biocompatible
                           silicon in/on the body

         STATUS:           PCT phase with publication date 20th February 1997

2.       IMPLANTS FOR ADMINISTERING SUBSTANCES AND METHODS OF PRODUCING
         IMPLANTS: GB 9808052.6, WO 99/53898, FILED 17TH APRIL 1998.

         TOPIC AREAS:      6 month in-vivo test of porous Si in the
                           subcutaneous site; controlled and slow delivery of
                           drugs (eg: hormones or microminerals) from implanted
                           capsules, either via micromachined reservoirs and pSi
                           barriers or via pore-entrapment.

         CLAIMS:           erodable silicon implants containing beneficial
                           substances

         STATUS:           PCT phase with publication date 28th October 1999

3. DERIVATIZED POROUS SILICON: GB 9909996.2, WO 00/66190, FILED 1ST MAY 1999.

         TOPIC AREAS:      the use of derivitisation to improve the
                           stability and haemocompatibility of pSi for
                           therapeutic uses; stability tests were conducted
                           in-vitro in simulated human plasma. Implantable
                           devices proposed include biofilters, batteries,
                           microelectrodes, wound repair structures,
                           radiotherapy microparticles and mirrors.

         CLAIMS:           use of derivitised porous silicon in/on the body

         STATUS:           PCT phase with publication date 9th November 2000

PATENT 4; UNPUBLISHED BUT COMPLETE

4.       CANCER TREATMENT: GB 0104383.5, FILED  22ND FEBRUARY 2001.

         TOPIC AREAS:      pSi microparticles of tunable density, loaded
                           with either a radionuclide or cytotoxic drug for the
                           treatment of liver cancer.

         CLAIMS:           cytotoxic and biodegradable porous silicon
                           microparticles (tbf)

         STATUS:           2nd filing due on 22nd February 2002.

<PAGE>
                                      -40-

                                   SCHEDULE 5

                           SGHT INTELLECTUAL PROPERTY

Any and all Know-How related directly to the Field and owned by SGHT or SGH

<PAGE>
                                      -41-

IN WITNESS whereof this Agreement has been executed by duly authorised officers
of the Parties on the date first above written.

                           Signed by: /s/Pierce Chow
                                      ------------------------------------------
                                      Name:  Pierce Chow
                                      Title:  Director

                           For and on behalf of

                           PSIONCOLOGY PTE. LTD.

                           Witnessed By: /s/Tan Swee Gek
                                      ------------------------------------------
                                         Name: Tan Swee Gek
                                         Advocate & Solicitor, Singapore

                           Signed by: /s/ Ong Yong Yau
                                      ------------------------------------------
                                      Name: Professor Ong Yong Yau
                                      Title: Chief Executive Officer

                           For and on behalf of
                           SINGAPORE GENERAL HOSPITAL PTE LTD

                           Witnessed By: /s/Tan Swee Gek
                                      ------------------------------------------
                                         Name: Tan Swee Gek
                                               Advocate & Solicitor, Singapore

                           Signed by: /s/Wong Chiang Yin
                                      ------------------------------------------
                                      Name: Dr. Wong Chiang Yin
                                      Title: Director

                           For and on behalf of
                           SGH TECHNOLOGY VENTURES PTE LTD

                           Witnessed By: /s/Tan Swee Gek
                                      ------------------------------------------
                                         Name: Tan Swee Gek
                                               Advocate & Solicitor, Singapore[***] - INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES AND EXCHANGE
ACT OF 1934, AS AMENDED.

                      PROCESS DEVELOPMENT AND MANUFACTURING

                                    AGREEMENT

                                     BETWEEN

                                pSiMEDICA LIMITED

                                       AND

                             AEA TECHNOLOGY QSA GmbH

<PAGE>

                                     INDEX

ARTICLE 1 - DEFINITIONS                                                       5

ARTICLE 2 - PURPOSE                                                           8

ARTICLE 3 - TERM                                                              8

ARTICLE 4 - DEVELOPMENT PHASE                                                 8

ARTICLE 5 - FACILITY PROGRAM                                                  9

ARTICLE 7 - GENERAL MANUFACTURE AND SUPPLY OBLIGATIONS                       12

ARTICLE 8 - GENERAL OBLIGATIONS                                              13

ARTICLE 9 - PAYMENTS                                                         14

ARTICLE 10 - ORDERS AND SHIPMENTS                                            16

ARTICLE 11 - LICENSE                                                         18

ARTICLE 12 - pSiMEDICA REPRESENTATIONS AND WARRANTIES                        18

ARTICLE 13 - pSiMEDICA'S INTELLECTUAL PROPERTY INDEMNITY                     19

ARTICLE 14 - QSA'S REPRESENTATIONS AND WARRANTIES                            20

ARTICLE 15 - QSA'S INTELLECTUAL PROPERTY INDEMNITY                           21

ARTICLE 16 - ARISING INTELLECTUAL PROPERTY                                   22

ARTICLE 17 - REGULATORY MATTERS                                              24

ARTICLE 18 - GENERAL INDEMNITY                                               26

ARTICLE 19 - DISCLOSURE OF TECHNOLOGY                                        27

ARTICLE 20 - CONFIDENTIALITY                                                 27

ARTICLE 21 - TERMINATION                                                     28

ARTICLE 22 - NOTICES                                                         30

ARTICLE 23 - DISCLAIMER OF CONSEQUENTIAL DAMAGES                             31

ARTICLE 24 - ASSIGNMENT                                                      31

ARTICLE 25 - COMPLIANCE                                                      31

ARTICLE 26 - NON-WAIVER                                                      32

ARTICLE 27 - FORCE MAJEURE                                                   32

ARTICLE 28 - INSURANCE                                                       32

                                       2
<PAGE>

ARTICLE 29 SEVERABILITY                                                      34

ARTICLE 30 GENERAL                                                           34

ARTICLE 31 - APPLICABLE LAW                                                  35

Schedule A Development Phase                                                 37

Schedule B Facility Description                                              38

Schedule C Product Description (For Phase IIa Product)                       44

Schedule D Source Specifications                                             45

Schedule E Pricing                                                           49

                                       3
<PAGE>

THIS AGREEMENT made in duplicate this 15th day of March, 2004,

BETWEEN:      AEA TECHNOLOGY-QSA, GMBH
              having a place of business at
              Gieselweg 1
              D-38110, Braunschweig
              GERMANY

("QSA")

AND:          pSiMedica Ltd
              having a place of business at
              Malvern Hills Science Park
              Geraldine Road
              Malvem, Worcestershire,
              WR14 3SZ
              UNITED KINGDOM

("pSiMedica")

WHEREAS:

I.    pSiMedica is the owner of certain patents, data, information and
      technology related to a new biomaterial (BioSilicon(TM)) that it wishes to
      be the basis for a potentially new class of P-32 containing "sources" for
      use in intratumoural brachytherapy;

II.   QSA has expertise in the production and processing of radioactive
      material, including the necessary patents, know-how, techniques, methods,
      processes and trade secrets for the development and manufacture of sealed
      sources and dosimetry;

III.  pSiMedica desires that QSA manufactures P-32 BioSilicon(TM) "sources" to
      meet pSiMedica's commercial supply requirements; and

IV.   pSiMedica desires that QSA develops the required sources, construct a
      facility at its subsidiaries sites, initially at Braunschweig, Germany,
      and then to manufacture pSiMedica's requirements for P-32 BioSilicon(TM)
      sources, in accordance with the terms, conditions and specifications set
      out herein.

                                       4
<PAGE>

NOW THEREFORE in consideration of the mutual covenants and agreements herein
contained, and subject to the terms and conditions hereinafter set out, the
Parties hereto agree as follows:

                             ARTICLE 1 - DEFINITIONS

For the purposes of this Agreement:

1.1   "Affiliated Company" shall mean either

      (a) a company which is at least majority owned or majority controlled by a
      Party hereto or which holds at least a majority interest or majority
      control in such Party;

      or

      (b) a parent company to one of the Parties hereto

1.2   "Batch" shall mean a production batch of P-32 BioSilicon(TM) manufactured
      by QSA under this Agreement.

1.3   "Background Technology" shall mean all QSA or its Affiliated Company(s)
      proprietary technology, including patents, copyrights, know-how,
      techniques, methods, processes and trade secrets which is required for the
      purposes of performing the obligations of QSA under this Agreement and
      which is owned by QSA or its Affiliated Company(s), or which QSA is
      authorized to use, or which is licensed to QSA from third parties and
      which is in existence in the form of a written, description, prototype or
      can otherwise be demonstrated to be the property of QSA or its Affiliated
      Company(s), prior to the Effective Date.

1.4   "Clinical Trials" shall mean human trials for clinical development of the
      Medical Device.

1.5   "Commercial Phase" shall mean the period commencing at the date of the
      first commercial sale of P-32 BioSilicon(TM) Sources from QSA to pSiMedica
      which have been manufactured in the Facility, for pSiMedica after receipt
      of marketing authorization from the appropriate Regulatory Authorities and
      ending at the date of the last commercial sale of P-32 BioSilicon(TM)
      Sources from QSA to pSiMedica.

1.6   "Development Phase" shall mean the period commencing from the Effective
      Date until completion to pSiMedica's reasonable satisfaction of the
      activities described in Schedule A and any other schedules referred to in
      Schedule A.

1.7   "Effective Date" shall mean the date of the signature of this Agreement.

                                       5
<PAGE>

1.8   "Equipment(s)" shall mean the moveable assets to be purchased or
      manufactured by QSA for and on behalf of pSiMedica. Said equipment will be
      detailed in project invoices from QSA to pSiMedica and will be clearly
      tagged and identified as pSiMedica property.

1.9   "European Authority" shall mean pSiMedica's Notified Body.

1.10  "Facility" shall mean the production line facility to be constructed by
      QSA in its currently existing factory in Braunschweig, Germany, as
      described in Schedule B and which will be constructed and installed for
      the production of Sources.

1.11  "Facility Program" or "Facility Phase" shall mean the program for the
      construction of the Facility as described in Article 5.

1.12  "Hot Cell(s)" shall mean the assets to be purchased or manufactured by QSA
      for and on behalf of pSiMedica and installed in the Facility for the term
      of this Agreement (unless QSA exercises the option under Article 6.1
      (ii)), as more specifically defined in Schedule "B".

1.13  "Improvements" shall mean the extension of Intellectual property gained
      during the Term of this Agreement

1.14  "Initial Term" shall have the meaning set forth in Article 3.1 hereof

1.15  "Initial Term Notice" shall mean the written notice by either Party which
      shall be given at least eighteen (18) months prior to the end of the
      Initial Term and by which the notifying Party informs the other Party that
      it does not wish to extend the term of the Agreement beyond the Initial
      Term.

1.16  "Isotope" or "P-32" shall mean the Phosphorous-32 in the medical device.

1.17  "Intellectual Property Rights" (IPR) shall mean all intellectual rights
      (including but not limited to) rights to inventions, patent rights,
      know-how, copyrights and design rights in any part of the world to the
      fullest extent and for the full period thereof (including without
      limitation any extensions, reversions and renewals) and all rights thereto
      and interests therein."

1.18  "Major Repair(s)" shall mean a repair to a given asset entailing
      expenditures in excess of the lesser of:

      (i)   [***] of the subject asset's purchase price as determined at the
            time of purchase by the invoice price less any discounts received,
            or

      (ii)  [***].

1.19  "Medical Device" shall mean pSiMedica's P-32 BioSilicon(TM) as described
      in Schedule C.

                                       6
<PAGE>

1.20  "Minimum Batch Size" shall mean the minimum number of dose vials to be
      assembled in one batch and the number of which is to be mutually agreed in
      writing prior to the commencement of the Commercial Phase.

1.21  "Notice of Termination" shall mean the written notice given by either
      Party to the other Party to terminate the Agreement after the Initial Term
      has ended. Notice of Termination must be given at least eighteen (18)
      months prior to the date of effective termination.

1.22  "pSiMedica Notified Body" shall mean the appropriately designated medical
      authority.

1.23  "pSiMedica Technology" shall mean all pSiMedica proprietary technology,
      including patents, know-how, techniques, methods, processes and trade
      secrets which is required for the purposes of performing the obligations
      of pSiMedica under this Agreement and which is owned by pSiMedica, or
      which pSiMedica is authorized to use, or which is licensed to pSiMedica
      from third parties and which is in existence in the form of a written,
      description, prototype or can otherwise be demonstrated to be the property
      of pSiMedica, prior to the Effective Date.

1.24  "Process" shall mean the process of formulation, irradiation, preparation,
      dispensing into dose vials, encapsulation, de-encapsulation,
      re-encapsulation, inspection and testing of Sources to meet pSiMedica's
      Specification.

1.25  "QSA Repairs" shall mean repairs or maintenance to the Equipment and Hot
      Cells that are necessary through QSA's negligent abuse, improper
      operation, inadequate maintenance, negligence or willful misconduct.

1.26  "Scheduled Batch Completion Date" The date for which QSA has received
      final confirmation from pSiMedica that a Batch is required. Such
      confirmation from pSiMedica will be given at intervals no less than 14
      (fourteen) days prior to when dispatch is required by pSiMedica

1.27  "Specification(s)" shall mean those specifications for the Sources set out
      in Schedule D.

1.28  "Source(s)" shall mean the terminally sterilized patient dose vial
      produced using the Process which meet the Specifications.

1.29  "Dose vial(s)" shall mean Sources dispensed to an agreed contained
      activity and reference date meeting the Specifications suitable for use in
      the Medical Device.

1.30  "Transfer Date" shall have the meaning set forth in Article 6.1 sub-clause
      (v) hereof.

                                       7
<PAGE>

1.31  "United States Authority" shall mean the United States Food and Drug
      Administration.

1.32  "Validation" shall mean the program mutually agreed to by the Parties by
      which documented evidence provides assurance that the Process will
      consistently produce Sources that meet Specifications and quality
      attributes, to the reasonable satisfaction of both Parties and the
      appropriate Regulatory Authorities.

                              ARTICLE 2 - PURPOSE

2.1   SCOPE AND OBJECT

      The scope and object of the Agreement is to complete the development of
      Sources in accordance with the development responsibilities and
      obligations attributed to each of the Parties as set out in this
      Agreement. In addition, this Agreement shall provide for the construction
      of a Facility at QSA's manufacturing site in Braunschweig, Germany, for
      the manufacture of Sources and the supply of Sources for Clinical Trials
      and initial commercial sales. It is anticipated that later duplication of
      the Facility may be required at other QSA subsidiary sites in order to
      follow market demands.

                                ARTICLE 3 - TERM

3.1   INITIAL TERM

      The initial term of this Agreement shall commence upon the Effective Date
      and, unless terminated earlier pursuant to this Agreement, shall continue
      until the third anniversary of the commencement of the Commercial Phase
      ("Initial Term").

3.2   EXTENSION

      The term of this Agreement shall be automatically extended after
      expiration of the Initial Term unless either Party has given Initial Term
      Notice to the other Party. At least two years prior to the end of the
      Initial Term, the Parties agree to meet in order to discuss, in good
      faith, their intentions with respect to whether or not to continue the
      term of this Agreement beyond the Initial Term.

                         ARTICLE 4 - DEVELOPMENT PHASE

4.1   DEVELOPMENT ACTIVITIES

      During the Development Phase, QSA and pSiMedica shall respectively carry
      out their obligations described and attributed in Schedule "A", it being
      understood that some activities may be reasonably delayed to the extent
      that such activity is premised on the work or provision of data,
      information or technology by the other

                                       8
<PAGE>

      Party which such other Party does not provide on a timely basis. Each
      Party shall use their best efforts in order to carry out their respective
      obligations and responsibilities set out in Schedule "A" to the timescales
      specified.

      The Parties acknowledge and agree that Schedule "A" may only be amended
      during the course of the Development Phase to accommodate unforeseen
      events and results beyond the reasonable control of the Parties. All such
      changes to Schedule "A" shall be made by written agreement of the Parties.

      The Project Managers (as specified at Article 22.1) will meet at least
      bi-monthly, at locations to be agreed, including telephone or
      videoconferencing, for the purpose of reviewing the status of the project
      and to assess progress against the milestones and activities set forth in
      Schedule "A". QSA shall also provide written reports to pSiMedica, on a
      monthly basis, setting out the progress against milestones set forth in
      Schedule "A".

4.2   DEVELOPMENT PHASE TERMINATION

      At each review meeting of the Project Managers an assessment shall be made
      of the progress of the Development Stage and the ability of both Parties
      to fulfill the terms of this Agreement. Should both Parties agree in
      writing during the Development Phase that it is no longer possible to
      fulfill the terms of this Agreement, then this Agreement shall be
      terminated.

                          ARTICLE 5 - FACILITY PROGRAM

5.1   CONSTRUCTION OF FACILITY

      Subject to successful completion of the relevant parts of the Development
      Phase to the satisfaction of pSiMedica, QSA shall construct the Facility
      at its site in Braunschweig, Germany to carry out the manufacture of
      Sources. QSA will use its commercially reasonable best efforts to complete
      the Facility Program in accordance with the Gantt chart set forth in
      Schedule B. Schedule B may only be modified as agreed in writing by the
      Parties.

5.2   FACILITY PROGRAM CAPITAL COST

      The actual capital cost of the Facility Program will be calculated on a
      time and materials basis as set out in Article 9.1. The facility shall be
      completed by QSA on or about 18th May, 2005. The budgeted capital cost for
      performance of the Facility Program by QSA is estimated at the Effective
      Date to be One million two hundred and forty four thousand one hundred
      Euros.((euro) 1,244,100), inclusive of contingency and QSA administration
      fees. Any cost in excess of the estimated budgeted capital cost shall be
      subject to the prior written authorization of pSiMedica.

                                       9
<PAGE>

                          ARTICLE 6 - ASSET OWNERSHIP

6.1   EQUIPMENT

      (i)   Under this Agreement QSA will purchase or manufacture, on behalf of
            pSiMedica, the Hot Cell(s) and Equipment, which will be installed in
            the Facility as described in Schedule B. Upon completion of the
            purchase or manufacture of the Hot Cell(s) and Equipment, a warranty
            bill of sale in a form reasonably acceptable to pSiMedica, shall be
            executed and delivered to pSiMedica transferring full title to such
            Hot Cell(s) and Equipment dedicated to pSiMedica requirements free
            and clear of all liens, claims, or encumbrances. Subject to
            pSiMedica's obligations to transfer ownership of the Hot Cell to QSA
            under circumstances as set forth in this Agreement, pSiMedica shall
            at all times hold all right, title and interest in the Hot Cell and
            Equipment; provided, however, that during the term of this
            Agreement, usage thereof shall belong exclusively to QSA for the
            purposes of producing Sources for pSiMedica at the Braunschweig,
            Germany site. Since the Equipment will be in QSA's possession, QSA
            represents and warrants that the Hot Cell(s) and Equipment insofar
            as circumstances that are wholly under the control of QSA shall not
            be encumbered, and shall, during the term of this Agreement, remain
            free and clear of any and all encumbrances including, but not
            limited to, mortgages, charges and liens and that no effective
            financing statement, pledge or other instrument similar in effect
            covering all or any part of the Hot Cell(s) or Equipment has been
            agreed or will be agreed by QSA or Parties claiming by, through or
            under QSA.

      (ii)  In partial consideration of the services to be performed hereunder
            by QSA and in consideration of the payment of [***] the sufficiency
            of which is hereby acknowledged, on the earlier of the natural
            expiration or termination of this Agreement by pSiMedica (for
            whatever reason other than the default by QSA), should QSA wish to
            retain the use of the Hot Cell(s), pSiMedica agrees without further
            notice or demand to transfer all of its right, title and interest in
            and to the Hot Cell and Equipment to QSA. After transfer of title,
            QSA will following such transfer be responsible for any
            decontamination or decommissioning costs of the Facility.

      (iii) At the conclusion of this Agreement (for what ever reason) the Hot
            Cell and other dedicated Equipment at Braunschweig, will need to be
            decontaminated and decommissioned. This shall be the responsibility
            of pSiMedica unless QSA is able and chooses to exercise its option
            to acquire title to the Hot Cells and Equipment. At the time of the
            completion of the Facility, on or about 30th December, 2004,
            pSiMedica shall establish an Escrow Account for the estimated cost
            to Decontaminate and Decommission the Facility [***]This Escrow
            Account shall be funded either by an irrevocable letter of credit,
            and be held by pSiMedica's attorney. Should QSA decline to exercise
            its option, or fail to be allowed to exercise the option due to its
            default of this Agreement, to own the Hot Cell and the Equipment,
            then upon the natural expiration or termination of this Agreement by
            pSiMedica the funds established by PSiMedica in the "Decontamination
            and Decommissioning" Escrow Account or through the letter of credit
            will be made available to QSA and shall be used exclusively for the
            decontamination and decommissioning of the Hot Cell(s) and any other
            Equipment prior to their removal by pSiMedica from the Braunschweig
            site. Should QSA exercise the option to own the Hot Cell(s) and the
            Equipment, then the funds held in the Escrow Account will revert to
            pSiMedica or the letter of credit canceled. At each calendar year
            end during this Agreement, pSiMedica will increase or decrease the
            balance of the Escrow Account or the letter of credit to reflect the
            reasonable costs of Decontamination and Decommissioning as estimated
            by QSA. If the balance of the Escrow Account exceeds the funds
            necessary for Decontamination and Decommissioning, the excess shall
            be returned to pSiMedica immediately upon completion of
            Decontamination and Decommissioning.

                                       10
<PAGE>

      (iv)  Except as may be provided in accordance with Article 16.1 sub-clause
            (ii), in no event may QSA use or permit any third Party to use the
            Hot Cell(s) or Equipment for the manufacture of any Sources, any
            products which use technology of pSiMedica, or any products which
            could compete with the sale of Sources or the Medical Device
            (including the Source) by pSiMedica. If title to the Equipment and
            Hot Cell(s) is obtained by QSA, QSA may not sell, transfer, lease,
            or permit the use of the Hot Cell(s) or the Equipment by third
            parties without first notifying pSiMedica and providing pSiMedica
            the opportunity to match the terms of any such sale, transfer,
            lease, or permit. Should pSiMedica decline to exercise such an
            option to purchase or acquire use of the Equipment and Hot Cell(s)
            then QSA shall be relieved of all obligations under this Article.

      (v)   It is understood that pSiMedica may finance the purchase and
            construction of the Hot Cell(s) and Equipment through debt and
            provide a preferred security interest (Sicherungseigentum) in the
            Hot Cell(s) and Equipment to a financing institution or other
            lender. Until such time as pSiMedica has made the transfer as set
            out in Article 6.1sub-clause(ii) or has otherwise transferred
            ownership of the Hot Cell(s) or Equipment as set out elsewhere in
            this Agreement (the "Transfer Date"), QSA shall have, and is hereby
            granted a secondary security interest (nachrangiges
            Anwartschaftsrecht auf Sicherungseigentum) in and to the Hot Cell(s)
            behind any security interest provided to any financing institution
            or other lender. The secondary security interest in the Hot Cell(s)
            and the provision for eventual Decontamination and Decommissioning
            set forth above shall be perfected by possession of the Hot Cell(s)
            by QSA and shall be effective as of the date of commencement of
            installation of such Hot Cell(s) and shall serve as collateral for
            the carrying out of the obligations of pSiMedica set out in this
            Agreement. Until the Transfer Date, QSA at all times during the Term
            of this Agreement shall be entitled to the use and possession of the
            Hot Cell(s) and Equipment in accordance with this Agreement, and the
            Hot Cell(s) and Equipment, shall be maintained and preserved by QSA
            at its expense in accordance with the provisions set out in this
            Agreement. pSiMedica shall execute all documents reasonably required
            to provide a secondary security interest in and to the Hot Cell(s)
            to QSA.

                                       11
<PAGE>

      (iv)  The labor rates and material handling markups on assets constructed
            by QSA or its affiliates for this Phase are set forth at Article 9.1
            hereto.

             ARTICLE 7 - GENERAL MANUFACTURE AND SUPPLY OBLIGATIONS

7.1   SOURCE SUPPLY

      QSA agrees to use the Process to produce Sources that meet the
      Specifications in conformity with all applicable laws, rules and
      regulations of Germany, the European Union and the United States and to
      ship Sources as directed by pSiMedica. Subject to the provisions of
      Article 27, during the Initial Term of this Agreement and any renewal or
      extension thereof, QSA shall manufacture as provided in the preceding
      sentence and provide pSiMedica with Sources which shall be ordered by
      pSiMedica under this Agreement for the purposes of clinical trials and
      commercial sale of the Medical Device.

7.2   BATCH SIZE AND MINIMUM PURCHASE COMMITMENT

      pSiMedica agrees that it shall order Sources at the price set forth in
      Article 9.3 in batch sizes no smaller than the Minimum Batch Size.
      pSiMedica further agrees that it shall purchase from QSA a minimum of
      [***] Sources during each twelve months period after commencement of the
      Commercial Phase for the remaining period of this Agreement. Should
      pSiMedica not order the minimum number of Sources in any twelve month
      period from the commencement of the Commercial Phase, then it shall pay
      QSA a penalty of [***] for the difference between the number of actual
      Sources ordered and the minimum purchase requirement for that period.

7.3   TESTING AND DOCUMENTATION

      QSA shall certify in writing, to pSiMedica, and shall provide backup
      evidence as requested, that each Batch of Sources was produced and tested
      in compliance with:

      (i)   the Specifications; and

                                       12
<PAGE>

      (ii)  all applicable laws, rules and regulations of Germany, the European
            Union and the United States, and in accordance with procedures
            agreed between pSiMedica and QSA.

      The tests and analyses provided in the Specifications as well as the
      nature and form of written certification may be amended from time to time
      only by mutual written consent of the Parties.

7.4   REPAIRS AND MAINTENANCE

      After the Facility is installed, QSA shall maintain such Facility, Hot
      Cell(s) and Equipment in satisfactory operating condition, as required to
      enable QSA to manufacture Sources to Specification in accordance with the
      Process and all other applicable laws, regulations, rules or orders. In
      the event of any conflict between the applicable laws, regulations, rules
      or orders, QSA will notify pSiMedica of such conflict and the Parties
      shall act in good faith to resolve such conflict or to determine which
      laws, regulations, rules or orders should take precedence. Routine
      repairs, preventive maintenance and service contracts for the Facility and
      Equipment shall be arranged by QSA.

                        ARTICLE 8 - GENERAL OBLIGATIONS

8.1   ISOTOPE SUPPLY

      QSA shall obtain reactor irradiation space sufficient to meet its
      obligations hereunder.

      QSA shall contract for the supply of the irradiation facility(ies) to
      produce the Isotope necessary for QSA's production of Sources pursuant to
      this Agreement.

8.2   UNAVAILABILITY OR SCARCITY OF REACTOR IRRADIATION

      It is understood that QSA's obligation to supply Isotope is conditional,
      depending upon its ability to obtain a sufficient supply of the Isotope by
      the reactor irradiation of feedstock doped BioSilicon(TM) supplied by
      pSiMedica. QSA will use its best efforts to locate and obtain sufficient
      reactor space to produce Isotope to manufacture the Sources required by
      pSiMedica. QSA will notify pSiMedica upon QSA's first knowledge of a
      shortage or likelihood of any shortage of Isotope if such shortage will
      impact the manufacture of the Sources. Except as set out below, QSA shall
      not be liable for any delays in the supply of Isotope if due to causes
      described in Article 27 hereof.

8.3   PRODUCTION PLANNING FOR CLINICAL TRIAL AND COMMERCIAL SUPPLY

      During the first five (5) business days of each month commencing with the
      Commercial Phase of this Agreement, QSA and pSiMedica will establish a
      schedule of Batch runs for the next twelve (12) weeks. pSiMedica shall
      provide QSA with confirmation of Batch orders no later than fourteen (14)
      days prior to a Scheduled Batch Completion Date. QSA shall be under an
      obligation to deliver to pSiMedica the confirmed Batch order within the
      agreed time schedule for such delivery. This approach to production
      planning may be modified as mutually agreed to by the Parties based upon
      pSiMedica's and QSA's experience in clinical and commercial supply.

                                       13
<PAGE>

                              ARTICLE 9 - PAYMENTS

9.1   DEVELOPMENT AND FACILITY PROGRAM

      As with the previous Agreements signed by the two Parties hereto, in
      performing the Development Phase QSA will invoice pSiMedica monthly in
      arrears, providing an adequate description of the work billed. [***]

      In the Facility Program, QSA will provide labor at the hourly billing
      rates detailed at Schedule A, [***].

      All charges not included in Schedule A or B hereto shall be subject to the
      prior written approval of pSiMedica. Charges shall be due only for
      services, material and equipment authorized by the terms of Schedule A or
      Schedule B. Monthly invoices that include detailed cost statements shall
      be submitted to pSiMedica for work performed during the prior month.

      [***]

9.2   PAYMENT FOR REPAIRS AND MAINTENANCE

      QSA shall be responsible for the payment of all repair and maintenance
      costs. pSiMedica will repay all reasonable expenses for any Major Repairs
      to or replacement of the Equipment except for QSA Repairs. All costing for
      all repairs shall be on the same basis as the Facility Phase.

      The maximum amount QSA will be required to pay in any calendar year for
      routine repairs, preventive maintenance and service contracts for the
      Facility and Equipment shall be [***], plus all amounts required for QSA
      Repairs. Any reasonable amounts for routine repairs, preventive
      maintenance and service contracts for the Facility and Equipment other
      than QSA Repairs in excess of [***] in any calendar year will be borne by
      pSiMedica. Preventive maintenance and service contracts for the Equipment
      in excess of [***] which are approved in advance by pSiMedica will be
      borne by pSiMedica. All amounts set forth in this Article shall be based
      on [***] QSA shall co-ordinate with and advise pSiMedica regarding the
      advisability of any Major Repair or replacement. The only repairs, if any,
      to the Facility or Equipment which shall be borne by pSiMedica are those
      set forth in this Article. All other repairs shall be borne by QSA.

                                       14
<PAGE>

9.3   PURCHASE PRICE FOR SOURCES

      Prior to the commencement of the Commercial Phase, the Parties shall agree
      the price that shall be paid by pSiMedica for each Source that QSA
      produces to Specification. [***]

9.4   [***]

9.5   PAYMENT TERMS

      Except as otherwise provided herein, all invoices shall be paid within 30
      days. Where there is any dispute with regard to any item on any cost
      statement and or invoice, payment for that item shall be withheld until
      such time as any dispute is settled. Payment shall not be withheld from
      any item that is not under dispute.

      All payments, costs and prices included in this Agreement shall be
      exclusive of all taxes.

9.6   CURRENCY

      Unless otherwise specified, all sums set out in this Agreement shall be in
      Euros.

                                       15
<PAGE>

9.7   AUDIT

      QSA shall keep accurate books and accounts of record in connection with
      the manufacture by it of the Sources in sufficient detail to permit
      accurate determination of all figures necessary for verification of all
      compensation required to be paid pursuant to Article 9. QSA shall maintain
      such records for a period of three (3) years after the end of the year in
      which they were generated. These records may be audited by pSiMedica in
      accordance with this Agreement, and shall be available for review by
      pSiMedica at any time upon reasonable notice.

      Except as provided below, pSiMedica, at its sole expense and through its
      accounting personnel or, if pSiMedica elects, through an independent
      certified public accountant reasonably acceptable to QSA, shall have the
      right to examine the books and records of QSA relating to the activities
      of QSA hereunder and compensation due QSA hereunder for the sole purpose
      of verifying such statements. Such audit shall be conducted upon six (6)
      weeks' prior written notice to QSA during ordinary business hours, and
      shall not be more frequent than once during each calendar year. pSiMedica
      agrees to keep in strict confidence all information learned in the course
      of such audits, except when it is necessary to reveal such information in
      order to enforce its rights under this Agreement. pSiMedica's right to
      have such records examined shall survive termination or expiration of this
      Agreement for a period of one (1) year. As each Phase of this Agreement
      shall be priced and invoiced in a different manner, any financial audits
      undertaken by pSiMedica, shall be done in a way that is appropriate for
      the type of pricing and invoicing that was undertaken. In all events, QSA
      shall promptly remit to pSiMedica the amount of any overpayment, plus
      interest at the rate of 10% per annum from the date such payment was
      received by QSA until repaid to pSiMedica. In addition, if the audit
      reveals an overcharge of more than ten percent (10%) of the amount due,
      QSA shall reimburse pSiMedica for the cost of the related audit and any
      costs incident thereto, including attorney's fees and all costs of
      collection. Should such audits reveal that QSA have undercharged
      pSiMedica, then pSiMedica shall promptly remit to QSA such sums as have
      not been recovered.

                       ARTICLE 10 - ORDERS AND SHIPMENTS

10.1  ORDERS AND SHIPMENTS

      During the term of this Agreement, pSiMedica will forward orders to QSA by
      facsimile (or other suitable means). Such orders shall include the
      identity of the recipient and delivery destination. Delivery of Sources to
      pSiMedica or as otherwise directed by pSiMedica shall initially be
      ex-Works transport vehicle at QSA's facility in Braunschweig, Germany.
      Risk for the goods shall pass to pSiMedica at point of delivery to the
      transport vehicle. Title to the goods shall pass to pSiMedica upon QSA
      receiving payment from pSiMedica.

                                       16
<PAGE>

      During the term of this Agreement QSA shall subject to Article 27.1, meet
      pSiMedica's orders and delivery requirements.

      Prior to the first shipment of Sources to any third Party site, QSA shall
      obtain from such third Party its license evidencing proper legal authority
      for the receipt and possession of the Source by such third Party. If QSA
      is unable to obtain such license from the third Party, pSiMedica, upon
      QSA's request, shall obtain and provide such evidence of legal authority
      for the receipt and possession of the Source by such third Party.
      pSiMedica shall obtain all approvals, licenses and permits required to
      import the Source into any territory where pSiMedica directs shipments to
      be sent.

      QSA shall make shipping arrangement with carriers designated in writing by
      pSiMedica from the ex-Works point to the delivery site. All transportation
      and packaging costs incurred to deliver Sources ordered by pSiMedica shall
      be borne by pSiMedica.

10.2  BATCH NOT MEETING SPECIFICATIONS

      If either Party or its designee discovers that a Batch of Sources does not
      meet the Specifications, then the discovering Party shall promptly
      communicate in writing with the other Party to determine a mutually agreed
      course of action. With respect to any such Batch of Sources which do not
      meet Specifications as a result of shortcomings in process or parameters
      under the direct control of QSA, then QSA will promptly:

      (i)   replace such Batch of Sources at no additional cost (with QSA also
            paying all costs to deliver such replacement Batch to the pSiMedica
            designated site);

      (ii)  reimburse pSiMedica for its actual costs incurred to return the
            Sources to QSA and for any purchase price paid by pSiMedica for such
            Sources; and

      (iii) indemnify pSiMedica for any other costs it incurs by reason of such
            Batch of Sources or single Source not meeting Specifications. [***]

10.3  INVENTORY REQUIREMENTS

      Within one month of the commencement of the Commercial Phase of this
      Agreement, QSA shall maintain a reasonable minimum Source inventory of
      Sources to be agreed between the parties which will have a value according
      to the pricing agreed in Schedule E. This minimum inventory stock level
      shall be reviewed by QSA and pSiMedica at quarterly intervals to ensure
      compatibility with forecasted purchasing volumes. Upon Termination of this
      Agreement for any reason whatsoever, pSiMedica shall purchase the minimum
      inventory stock at QSA.

                                       17
<PAGE>

                              ARTICLE 11 - LICENSE

11.1  ROYALTY FREE LICENSES

      pSiMedica hereby provides to QSA a non-exclusive, non-transferable,
      royalty free license during the term of this Agreement to use pSiMedica
      Technology, for the sole purpose of assisting QSA in carrying out its
      obligations set out in this Agreement. QSA hereby provides to pSiMedica a
      non-exclusive, non-transferable, royalty free license during the term of
      this Agreement to the Background Technology, for the sole purpose of
      assisting pSiMedica in carrying out its obligations set out in this
      Agreement.

             ARTICLE 12 - PSIMEDICA REPRESENTATIONS AND WARRANTIES

12.1  PSIMEDICA REPRESENTATIONS AND WARRANTIES

      pSiMedica represents, warrants and covenants that:

      (i)   it has full right, power and authority to enter into this Agreement;

      (ii)  it is the owner or licensee, in Germany, the United Kingdom and the
            United States, of the patents, data, information and technology
            supplied to QSA by pSiMedica to assist QSA in carrying out its
            obligations hereunder;

      (iii) exercise of the patent(s) and technology provided by pSiMedica do
            not, to pSiMedica's best information and belief, infringe any
            patents, copyright or other industrial or intellectual property
            rights of third parties;

      (iv)  it has the right to provide any license and right to permit QSA to
            use the patents and technology related to the Sources provided to
            the extent required to assist QSA in carrying out its obligations
            under this Agreement;

      (v)   it has not received any notice of adverse claim or infringement of
            any patent or misappropriation of trade secrets in connection with
            the use and exploitation of the patents, data, information and
            technology provided hereunder and related to the Sources; and

      (vi)  this Agreement has been duly authorized by all necessary corporate
            action and constitutes a valid and binding agreement of pSiMedica,
            enforceable in accordance with its terms.

      (vii) it has complied with all corporate formalities required to legally
            bind it to this Agreement;

      (viii) it has executed no agreement in conflict herewith;

                                       18
<PAGE>

      (ix)  it shall exercise its rights and engage in activities hereunder in a
            workmanlike manner, using reasonable care and

      (x)   it shall at its sole cost and expense, comply with all laws and
            regulations and obtain all governmental approvals, regulatory
            approvals applicable to the exercise its rights and the engagement
            of its activities under this Agreement

      The foregoing representations and warranties shall be in lieu of and shall
      exclude all other warranties (as conditions) expressed or implied,
      statutory or otherwise, including any implied warranties (as conditions)
      of merchantability or fitness for a particular purpose.

            ARTICLE 13 - PSIMEDICA'S INTELLECTUAL PROPERTY INDEMNITY

13.1  INDEMNIFICATION OF QSA

      pSiMedica hereby agrees to indemnify, defend and hold QSA, its Affiliates
      and all of the officers, directors, employees, and agents of QSA and its
      Affiliates harmless from any and all damages directly suffered by them
      arising out of or related to (a) the breach or falsity of any
      representation of pSiMedica contained herein or (b) the negligent or
      willful misconduct of pSiMedica or its officers, directors, employees or
      agents, or (c) any breach by pSiMedica of its obligations hereunder.

      pSiMedica shall indemnify and hold QSA harmless from and against any
      liabilities, claims, damages and expenses (including reasonable attorney's
      fees) which QSA may be compelled to pay in any judgment, claim or action
      arising from infringement, of third Party copyright, patents, technology
      or other intellectual property rights, resulting from QSA's use, in
      accordance with the this agreement, of any data, information, technology
      or patents, as provided by pSiMedica hereunder. QSA shall give written
      notice of any such legal action promptly after QSA's first knowledge
      thereof. pSiMedica shall have sole and exclusive control of the defense of
      any legal action, including the choice and direction of any legal counsel.
      QSA may not settle nor compromise any legal action without the prior
      written consent of pSiMedica. This indemnity shall survive termination of
      the Agreement.

      This Article shall not apply to any liability resulting from the use of
      the aforementioned intellectual property for unauthorized purposes.

      In the event that any portion of the pSiMedica Technology is, in
      pSiMedica's reasonable opinion, likely to or does become the subject of a
      claim for a patent, copyright or other industrial or intellectual property
      rights infringement, pSiMedica reserve the right and may at its option:

                                       19
<PAGE>

      (i)   procure the right to continue using the pSiMedica Technology; or

      (ii)  modify the pSiMedica Technology to become non-infringing.

               ARTICLE 14 - QSA'S REPRESENTATIONS AND WARRANTIES

14.1  QSA'S REPRESENTATIONS AND WARRANTIES

      QSA represents, warrants and covenants that:

      (i)   It has full right and authority to enter into this Agreement;

      (ii)  It is the owner or has legal rights of use of its data, information
            and technology contributed with respect to the Process;

      (iii) The data, information and technology contributed by QSA does not, to
            QSA's best information and belief, infringe any patents, copyright
            or other industrial or intellectual property rights of third
            parties;

      (iv)  It has not received any notice of adverse claim of infringement of
            any patent or misappropriation of trade secret or any other
            intellectual property rights in connection with the use and
            exploitation of the data, information and technology used with
            respect to the Process;

      (v)   There is no action or proceeding pending or insofar as QSA knows or
            ought to know, threatened against QSA before any court,
            administrative agency or other tribunal which might have a material
            adverse effect on QSA's business; and

      (vi)  This Agreement has been duly authorized by all necessary corporate
            and government action and constitutes a valid and binding agreement
            of QSA, enforceable in accordance with its terms.

      (vii) it has complied with all corporate formalities required to legally
            bind it to this Agreement;

      (viii) it has executed no agreement in conflict herewith;

      (ix)  it shall exercise its rights and engage in activities hereunder in a
            workmanlike manner, using reasonable care and

      (x)   it shall at its sole cost and expense, comply with all laws and
            regulations and obtain all governmental approvals, regulatory
            approvals applicable to the exercise its rights and the engagement
            of its activities under this Agreement

                                       20
<PAGE>

14.2  SOURCE PRODUCT WARRANTY

      QSA warrants that the Product will be free from defects and conform to
      pSiMedica's specification but QSA's sole liability for breach of this
      warranty shall be as stated in Article 10.2 provided that the failure or
      defect is shown to QSA's reasonable satisfaction to be due to QSA's faulty
      workmanship, material or packaging and not to any defect in pSiMedica's
      Background Technology.

      The period of warranty in this Article 14.2 shall extend for a period of
      60 days from the date of receipt of the Product by pSiMedica or
      pSiMedica's customers or the end of the Product expiry date, whichever is
      sooner.

               ARTICLE 15 - QSA'S INTELLECTUAL PROPERTY INDEMNITY

15.1  INDEMNIFICATION OF PSIMEDICA

      QSA hereby agrees to indemnify, defend and hold pSiMedica, its Affiliates
      and all of the officers, directors, employees and agents of pSiMedica and
      its Affiliates harmless from any and all damages arising out of or related
      to (a) the breach or falsity of any representation of QSA contained
      herein, (b) the negligent or willful misconduct of QSA or its officers,
      directors, employees or agents, or (c) any breach by QSA of its
      obligations hereunder, including without limitation its obligation to
      comply with standard operating procedures.

      QSA agrees to defend, indemnify and hold pSiMedica, its officers,
      directors and employees harmless from and against any liabilities, claims,
      damages and expenses (including reasonable attorneys' fees) which
      pSiMedica and such indemnified Parties may be compelled to pay in any
      judgment, claim or action arising from infringement of third Party
      copyright, patents, technology or other intellectual property rights
      resulting from pSiMedica's use under this Agreement of Background
      Technology. pSiMedica shall give written notice of any legal action
      promptly after pSiMedica's first knowledge thereof. QSA shall have sole
      and exclusive control of the defense of any legal action, including the
      choice and direction of any legal counsel. pSiMedica may not settle nor
      compromise any such legal action without the written consent of QSA. This
      indemnity shall survive termination of this Agreement.

      In the event that any portion of the Background Technology developed is,
      QSA's reasonable opinion, likely to or does become the subject of a claim
      for a patent, copyright or other industrial or intellectual property
      rights infringement, QSA reserves the right and may at its option:

      (i)   procure the right to continue using the technology; or

      (ii)  modify the technology to become non-infringing.

                                       21
<PAGE>

15.2  ARISING INTELLECTUAL PROPERTY INDEMNITY

      In the event that any portion of the technology developed under this
      Agreement is, in either Parties reasonable opinion, likely to or does
      become the subject of a claim for a patent, copyright or other industrial
      or intellectual property rights infringement, either Party reserves the
      right and may at its option:

      (i)   procure the right to continue using the technology; or

      (ii)  modify the technology to become non-infringing.

                   ARTICLE 16 - ARISING INTELLECTUAL PROPERTY

16.1  OWNERSHIP OF IMPROVEMENTS

      All Intellectual Property Rights in any Improvements conceived, written,
      created, developed or first reduced to practice in and related to the
      performance of this Agreement that relate to the pSiMedica Technology or
      BioSilicon(TM) generally ("pSiMedica Improvements") will be owned solely
      by pSiMedica irrespective of who conceives, writes, creates, develops or
      first reduces to practice any such Improvements.

      All Intellectual Property Rights in any Improvements conceived, written,
      created, developed or first reduced to practice in and related to the
      performance of this Agreement that relate to Background Technology ("QSA
      Improvements") will be owned solely by QSA irrespective of who conceives,
      writes, creates, develops or first reduces to practice any such
      Improvements.

      All Intellectual Property Rights in any Improvements conceived, written,
      created, developed or first reduced to practice in and related to the
      performance of this Agreement that do not relate to either the pSiMedica
      Technology or the Background Technology, will be jointly owned by
      pSiMedica and QSA, irrespective of who conceives, writes, creates,
      develops or first reduces to practice any such Improvements and both
      pSiMedica and QSA shall, except as otherwise stated in this clause, have
      free use of such Improvements. Each Party on behalf of its stockholders,
      directors, employees, officers, Subsidiaries and representatives hereby
      assigns to the other party all Intellectual Property Rights in all such
      jointly owned Improvements. However neither Party shall utilize such
      jointly owned Improvements in conjunction with any third party without the
      prior written approval of the other party, which approval if given may be
      subject to any conditions that the other party reasonably determines but
      shall not be unreasonably withheld.

      In the event that pSiMedica is acquired or assigns a manufacturing license
      for the production of its P-32 BioSilicon(TM) that results in production
      other than by utilising the ongoing services of QSA and pSiMedica assets
      residing at QSA facilities, then pSiMedica, its heirs, successors or
      assigns shall be entitled to:

                                       22
<PAGE>

      a)    use any QSA Improvement which is made, developed or acquired by QSA,
            for its own purposes by way of a non-exclusive license without limit
            of time in exchange for a reasonable royalty

      b)    use the relevant Background Technology necessary to operate the
            manufacturing process by way of a non-exclusive license without
            limit of time in exchange for a reasonable royalty

      QSA will do all acts and things necessary to become the owner of any
      intellectual property rights arising out of the performance of the
      Agreement and to which pSiMedica can possibly be entitled or have a right
      to. In particular, QSA should, after consultation with pSiMedica, be
      obliged to claim all rights to inventions of their employees invented in
      the performance of the Agreement

16.2  PSIMEDICA IMPROVEMENTS

      QSA:

      must notify pSiMedica in writing of all pSiMedica Improvements promptly
      following such Improvements being conceived, written, created, developed
      or first reduced to practice by any of its employees, officers, agents,
      contractors or other personnel engaged by QSA in and related to the
      performance of this Agreement; must upon pSiMedica's request, provide all
      details relating to any pSiMedica Improvements in a form specified by
      pSiMedica; hereby assigns all Intellectual Property Rights in all
      pSiMedica Improvements topSiMedica; and

      must do all things directed by pSiMedica, including executing such
      documents, which pSiMedica considers necessary in order to assign to
      pSiMedica and otherwise absolutely vest title in pSiMedica to all
      Intellectual Property Rights in such pSiMedica Improvements.

16.3  QSA IMPROVEMENTS

      pSiMedica:

      must notify QSA in writing of all QSA Improvements promptly following such
      Improvements being conceived, written, created, developed or first reduced
      to practice by any of its employees, officers, agents, contractors or
      other personnel engaged by pSiMedica in and related to the performance of
      this Agreement; must upon QSA's request, provide all details relating to
      any QSA Improvements in a form specified by QSA; hereby assigns all
      Intellectual Property Rights in all QSA Improvements to QSA; and must do
      all things directed by QSA, including executing such documents, which QSA
      considers necessary in order to assign to QSA and otherwise absolutely
      vest title in QSA to all Intellectual Property Rights in such QSA
      Improvements.

                                       23
<PAGE>

16.4  SURVIVAL OF ARTICLE 16

      This Article 16 shall survive the termination of this Agreement for any
      reason including expiration or termination of this Agreement.

                        ARTICLE 17 - REGULATORY MATTERS

17.1  PSIMEDICA RESPONSIBILITIES

      It shall be the responsibility of pSiMedica or its designee to file,
      obtain and maintain such licenses, registrations, listings, authorizations
      and approvals as the European Authority or United States Authority or any
      other applicable governmental entity may require to enable use of the
      Sources as a Medical Device. QSA shall provide to pSiMedica as requested
      or, at QSA's discretion directly to the regulatory authority (in order to
      protect the proprietary nature of the information), all required
      information in its possession necessary to assist pSiMedica in filing,
      obtaining and maintaining all licenses, registrations, listings,
      authorizations and approvals of any governmental entities necessary for
      the use of Sources as a Medical Device and in order to seek marketing
      authorization for the Medical Device.

17.2  QSA RESPONSIBILITIES

      QSA shall be responsible for obtaining and maintaining all necessary
      facility licenses, registrations, authorizations and approvals, other than
      those required to market the Medical Device or use it in clinical trials,
      which are necessary to develop, manufacture, handle, store, label,
      package, dispose of, transport and ship Sources and radioactive materials
      in the U.S., Germany, and other jurisdictions specified by pSiMedica.

17.3  GOVERNMENTAL INSPECTIONS, COMPLIANCE REVIEW AND INQUIRIES

      Upon request of any governmental entity or any third Party entity
      authorized by a governmental entity, such entity shall, for the purpose of
      regulatory review, have access to observe and inspect the Facility and
      procedures used for the manufacturing, testing, storage and shipping of
      Sources, including Process development operations, and to audit such
      Facilities for compliance with applicable regulatory standards, and to
      perform such other activity as such entity may be authorized to undertake.
      QSA shall give pSiMedica prompt notice of any upcoming inspections or
      audits by a government entity of the Facility or procedures and shall
      provide pSiMedica with a written summary of such inspection or audit
      following completion thereof. QSA agrees to use commercially reasonable
      efforts to promptly rectify or resolve any deficiencies noted by a
      government entity whether communicated orally, in a report or
      correspondence or otherwise issued to QSA.

                                       24
<PAGE>

17.4  ACCESS TO THE FACILITY

      pSiMedica shall have reasonable access to the Facility and procedures:

      (i)   at least once per calendar quarter and more frequently for good
            cause, for the purpose of observing the Process development relating
            to the Sources, and

      (ii)  no more frequently than semiannually (except for good cause) for the
            purpose of auditing the Facility for compliance to applicable
            regulatory requirements and standards relating to the Sources and
            timely performance by QSA of its obligations hereunder.

      After commencement of the Commercial Phase, pSiMedica shall, as mutually
      agreed and no less frequently than semiannually (except for good cause),
      be entitled to access to the Facility for the purpose of observing any
      Process development or to audit the Facility for compliance with
      specifications and other regulatory requirements. QSA shall provide access
      to pSiMedica, on a continuing basis, to all QSA protocols, standard
      operating procedures and manufacturing records, as is necessary or
      relevant for the development, manufacture, handling, storage, labeling,
      packaging, disposing, transportation and shipment of Sources, which may be
      required in obtaining or maintaining licenses, registrations,
      authorizations and regulatory authorization of the Medical Device. All
      such information disclosed to pSiMedica or its employees or agents, shall
      be deemed to be pSiMedica's Confidential Information as such term is
      defined in this Agreement.

17.5  APPROVAL FOR MANUFACTURING CHANGES

      QSA agrees that no changes will be made to any materials, Specifications,
      Equipment, Hot Cell(s) or methods of production or testing the Sources,
      without pSiMedica's prior written approval. Subsequent to such approval by
      pSiMedica, QSA may then make such approved changes in manufacturing
      procedures, so long as in any event:

      (i)   such changes are permitted by applicable government regulations and
            the terms of any licenses, registrations, authorizations or
            approvals previously granted by the applicable governmental entity
            with respect to the Medical Device, and

      (ii)  pSiMedica receives copies of all documentation relating to such
            approved changes.

      If the changes require the additional license, registration, authorization
      or approval of any applicable governmental entity in Europe, United States
      or elsewhere, such changes may not be implemented until QSA receives
      written notice that the governmental entity or entities has or have
      authorized or approved the change. Each Party shall cooperate fully with
      the other in preparing data and information for a submission requesting
      prior authorization or approval of a change in materials, specifications,
      equipment or methods of production or testing. However, where changes are
      required to be made at the request of a regulatory body, pSiMedica shall
      not withhold their agreement to such changes.

                                       25
<PAGE>

17.6  NEW REGULATORY REQUIREMENTS

      Each Party shall promptly notify the other of new regulatory requirements
      of which it becomes aware which are relevant to the manufacture of Sources
      under this Agreement and which are required by the European Authority,
      United States Authority or other applicable governmental entities and the
      Parties shall confer with each other with respect to the best means to
      comply with such requirements. QSA shall be responsible for implementing
      and complying with any new or revised regulatory requirements arising
      after the Effective Date relating to QSA's performance of this Agreement.

                         ARTICLE 18 - GENERAL INDEMNITY

18.1  HOLD HARMLESS

      QSA and pSiMedica, as the case may be, shall indemnify and hold harmless
      the other from and against any and all costs, claims, judgements or other
      expenses, including reasonable attorney fees, arising as a result of
      damages claimed by third parties, in tort, contract or other legal theory,
      or arising as a result of its violation of any applicable law or
      regulation, in each case occasioned by QSA's or pSiMedica's negligence or
      willfulness or that of their respective employees or agents, in carrying
      out their obligations hereunder.

18.2  INDEMNIFICATION PROCEDURES

      A Party (the "Indemnitee") which intends to claim indemnification under
      this Agreement shall promptly notify the other Party (the "Indemnitor") in
      writing of any action, claim or other matter in respect of which the
      Indemnitee, or any of their respective directors, officers, employees or
      agents intend to claim such indemnification; provided, however, the
      failure to provide such notice within a reasonable period of time shall
      not relieve the Indemnitor of any of its obligations hereunder except to
      the extent the Indemnitor is prejudiced by such failure. The Indemnitor
      shall have sole and exclusive control of the defense of any legal action,
      including the choice and direction of any legal counsel. The Indemnittee
      may not settle nor compromise any legal action without the written consent
      of the Indemnitor The Indemnitee, and its respective directors, officers,
      employees and agents shall cooperate fully with the Indemnitor and its
      legal representatives in the investigation and defense of any action,
      claim or other matter covered by this indemnification. The Indemnitee
      shall have the right, but not the obligation, to be represented by counsel
      of its own selection and at its own expense.

                                       26
<PAGE>

18.3  SURVIVAL OF ARTICLE

      This Article 18 shall survive the termination of this Agreement for any
      reason including expiration of the term.

                     ARTICLE 19 - DISCLOSURE OF TECHNOLOGY

19.1  DISCLOSURE

      Except as otherwise set out, it is agreed that disclosure of data,
      information or technology by QSA or pSiMedica, to the other, during the
      term of this Agreement shall not, except to the extent granted herein,
      constitute any grant, option or license under any patent, technology or
      other rights, held by QSA or pSiMedica.

                          ARTICLE 20 - CONFIDENTIALITY

20.1  CONFIDENTIALITY AND EXCEPTIONS

      During the term of this Agreement and for a period of ten (10) years
      thereafter, each Party hereto shall maintain in confidence all technology
      including Background Technology, pSiMedica Technology, Jointly Owned
      Arising IP and know-how, data, processes, methods, techniques, formulas,
      test data and other information disclosed to such Party by the other Party
      whether or not it is identified as "Confidential Information" by the
      disclosing Party (collectively "Confidential Information"). Each Party
      shall necessarily be free to disclose its own Technology under the terms
      of its own established process for the disclosure of its Confidential
      Information. If either Party needs to disclose Confidential Information
      pertaining to the manufacturing process covered by this Agreement to a
      third Party then this shall be accommodated by the creation of a three way
      Confidential Information disclosure agreement. This obligation of
      confidentiality shall not apply to the extent that it can be established
      by the Party in receipt of such Confidential Information, that the
      information:

      i)    was already known to the receiving Party at the time of disclosure;

      ii)   was generally available to the public or otherwise part of the
            public domain at the time of its disclosure;

      iii)  became generally available to the public or otherwise part of the
            public domain after its disclosure to the receiving Party through no
            act or omission of the receiving Party;

      iv)   was disclosed to the receiving Party by a third Party who had no
            obligation to restrict disclosure of such information; or

      v)    was independently developed by the receiving Party without any use
            of Confidential Information of the disclosing Party.

                                       27
<PAGE>

      Notwithstanding the foregoing, QSA and pSiMedica may both disclose
      Confidential Information to an Affiliate or permitted assign provided that
      the Affiliate or permitted assign is bound by confidentiality to the same
      extent as QSA and pSiMedica hereunder. The Party disclosing Confidential
      Information to such Affiliate or permitted assign shall be liable for any
      unauthorized use or disclosure of the Confidential Information by the
      Affiliate or permitted assign.

      This Article shall survive termination or expiration of this Agreement in
      accordance with its terms.

                            ARTICLE 21 - TERMINATION

21.1  TERMINATION FOR BREACH

      This Agreement may be terminated by either Party in the event of a
      material breach by the other Party of the terms and conditions hereof;
      provided, however, the other Party shall first give to the breaching Party
      written notice of the proposed termination of this Agreement (a "Breach
      Notice"), specifying the grounds thereof. Upon receipt of such Breach
      Notice, the breaching Party shall have ninety (90) days to respond by
      curing such breach. If the breaching Party does not cure such breach
      within such cure period, the other Party may terminate the Agreement
      without prejudice to any other rights or remedies which may be available
      to the non-breaching Party.

21.2  REMEDIES UPON TERMINATION BY QSA PURSUANT TO ARTICLES 21.1 OR 21.3

      If QSA terminates this Agreement, under Articles, 21.1 or 21.3, QSA, in
      addition to any claim for damages it may have, shall be entitled to:

      (i)   retain all amounts paid by pSiMedica to QSA prior to such
            termination;

      (ii)  except for the Hot Cell(s), return to pSiMedica all the Equipment
            which is owned by pSiMedica and in QSA's possession and for which
            pSiMedica has paid all amounts due to QSA pursuant to this
            Agreement, unless pSiMedica requests that QSA decommission the
            Equipment by using the funds in the Escrow Account;

      (iii) terminate all activities under this Agreement expeditiously so as to
            minimize costs incurred by pSiMedica therefor;

      (iv)  deliver all completed and undelivered Sources to pSiMedica, or
            destroy such Sources, as pSiMedica may elect.

      (v)   immediately upon such termination, except as provided elsewhere in
            this agreement, terminate all licenses granted by QSA to pSiMedica
            under this Agreement which rights shall revert back to QSA; and

                                       28
<PAGE>

      (vi)  where applicable receive from pSiMedica written confirmation that
            the foregoing steps have been taken and that it has ceased using all
            patents data, information, technology, trade secrets and other
            intellectual property owned by QSA pursuant to this Agreement.

      pSiMedica shall further reimburse QSA for all reimbursable costs and work
      necessarily and properly incurred in relation to the orderly cessation of
      the work and sums owing but not invoiced prior to the effective date of
      any such termination by QSA under this Agreement. In addition, pSiMedica
      will if QSA so opts, either promptly transfer title of the Hot Cell(s) to
      QSA or allow the execution of the Decontamination and Decommissioning work
      by using the funds in the Escrow Account, whereupon pSiMedica shall have
      no further obligations under Article 6. 1.

21.3  BANKRUPTCY

      Notwithstanding anything contained in this Agreement to the contrary, this
      Agreement may be terminated by either Party in the event the other Party
      files a petition in bankruptcy, is adjudicated a bankrupt, or files a
      petition or otherwise seeks relief under or pursuant to any bankruptcy,
      insolvency or reorganization statute or proceeding, or if a petition in
      bankruptcy is filed against it which is not dismissed within sixty (60)
      days or proceedings are taken to liquidate the assets of such Party which
      are not stayed within sixty (60) days. Any assets jointly owned by the two
      Parties including the Jointly Owned Arising IP shall become the property
      of the Party not seeking such relief.

21.4  REMEDIES UPON TERMINATION BY PSIMEDICA PURSUANT TO ARTICLE 21.1 OR ARTICLE
      21.3

      If pSiMedica terminates this Agreement under Article 21.1 or under Article
      21.3, or under any other provision hereof, pSiMedica, in addition to any
      claim for damages it may have, shall be entitled to:

      (i)   within thirty (30) days of such termination at QSA's expense if
            termination is caused by a breach of QSA's or at pSiMedica's if
            termination is for any other reason, receive the Equipment and all
            related materials, in its then current condition (subject to
            decontamination);

      (ii)  exercise the option whether the Hot Cell(s) shall be returned to
            pSiMedica by QSA or whether they shall be decontaminated and
            decommissioned by QSA by using the funds in the Escrow Account;

      (iii) receive all completed Sources which have been ordered but not
            delivered;

      (iv)  immediately upon such termination, terminate all licenses granted by
            pSiMedica to QSA under this Agreement which rights shall revert back
            to pSiMedica and QSA shall then destroy all Sources pSiMedica elects
            not to acquire; and

                                       29
<PAGE>

      (v)   receive from QSA written confirmation that the foregoing steps have
            been taken and that it has ceased using all patents data,
            information, technology, trade secrets and other intellectual
            property owned by pSiMedica pursuant to this Agreement.

      If pSiMedica terminates this Agreement, pSiMedica shall reimburse QSA for
      all reimbursable costs and work necessarily and properly incurred in
      relation to the orderly cessation of the work and sums owing but not
      invoiced prior to the effective date of any such termination by pSiMedica
      under this Agreement. In addition, pSiMedica will if QSA so opts, either
      promptly transfer title of the Hot Cell(s) to QSA or allow the execution
      of the Decontamination and Decommissioning work by using the funds in the
      Escrow Account, whereupon pSiMedica shall have no further obligations
      under Article 6. 1.

21.5  CONSEQUENCES OF TERMINATION OR EXPIRATION

      Notwithstanding expiration or termination of this Agreement, the
      obligations of the Parties under Articles 21 shall survive termination of
      this Agreement.

                              ARTICLE 22 - NOTICES

22.1  Within thirty (30) days after execution of this Agreement, the Parties
      shall each designate a Project Manager, who shall be responsible for
      coordinating communication and monitoring performance under this
      Agreement. All references in this Agreement to changes to the Schedules
      shall be automatically approved if agreed in writing by both Parties
      Project Managers.

22.2  Any notice to be sent to a Party hereunder except with regard to changes
      to the Schedules hereto shall be forwarded to:

22.3  QSA at:          AEA TECHNOLOGY-QSA, GMBH
                       Gieselweg 1
                       D-38110, Braunschweig
                       GERMANY

      Attention:       Dr. Rainer Lambrich

      PSiMedica at:    pSiMedica Ltd
                       Malvern Hills Science Park
                       Geraldine Road
                       Malvem, Worcestershire, WR14 3SZ
                       UNITED KINGDOM

      Attention:       Dr. Roger Aston

                                       30
<PAGE>

      Any notice required or authorized to be given by a Party to the other in
      accordance with the provisions of this Agreement shall, unless otherwise
      specifically stipulated, be in writing and delivered personally, overnight
      courier or electronic facsimile confirmed by registered mail.

                ARTICLE 23 - DISCLAIMER OF CONSEQUENTIAL DAMAGES

23.1  DISCLAIMER

      In no event shall either Party be liable to the other for indirect,
      contingent, incidental, special or consequential damages, including, but
      not limited to, any claim for damages based on lost profits, cost of
      capital, loss of business opportunity or loss of time.

                            ARTICLE 24 - ASSIGNMENT

24.1  NO ASSIGNMENT

      This Agreement shall endure to the benefit of and shall be binding upon
      the heirs, executors, administrators, successors and permitted assigns of
      the Parties. Neither QSA nor pSiMedica shall assign any portion of this
      Agreement without the written approval of the other Party, which approval
      shall not be unreasonably withheld. However, either Party has the right to
      assign this agreement to an Affiliate, but in such case shall remain
      liable to the other Party for the performance of its Affiliate and shall
      indemnify the other Party and hold it harmless from and against all costs,
      claims, judgements and other expenses arising from the Affiliate's
      performance or failure of performance.

      QSA shall be entitled to subcontract to third parties any of its
      obligations set out in this Agreement in order to carry out its
      obligations hereunder; provided, however, that QSA may not subcontract any
      obligation in this Agreement unless such subcontractor shall agree to be
      bound by all of the relevant provisions hereof. QSA shall remain
      responsible for the performance of its subcontractors and shall indemnify
      pSiMedica and hold it harmless from and against any and all costs, claims,
      judgments or other expenses arising from any subcontractor's performance
      or failure of performance.

                            ARTICLE 25 - COMPLIANCE

25.1  COMPLIANCE WITH LAWS

      This Agreement shall be carried out in compliance with all relevant laws,
      bylaws, rules, regulations and orders of government or manifestations
      thereof of Germany, the European Union and the United States.

                                       31
<PAGE>

                            ARTICLE 26 - NON-WAIVER

26.1  NON-WAIVER OF RIGHTS

      Failure by either Party to enforce at any time any of the provisions of
      this Agreement shall not be construed as a waiver of its rights hereunder.
      Any waiver of a breach of any provision hereof shall not affect either
      Party's rights in the event of any additional breach.

                           ARTICLE 27 - FORCE MAJEURE

27.1  FORCE MAJEURE

      Neither Party shall be liable to the other for loss or damage by virtue of
      the occurrence of an event of Force Majeure. In the event of Force
      Majeure, the Party affected shall promptly notify the other and shall
      exert commercially reasonable efforts to eliminate, cure or overcome such
      event and to resume performance of its obligations. If QSA is the Party
      affected by the Force Majeure event, QSA agrees that it will resume
      production of Sources as soon as practicable thereafter. For such time as
      QSA is affected by an event of Force Majeure, PSiMedica is relieved from
      its purchase obligations under this Agreement which purchase commitments
      shall be adjusted accordingly on a pro rated annual basis. "Force Majeure"
      shall mean an occurrence which prevents, delays or interferes with the
      performance by a Party of any of its obligations hereunder, if such event
      occurs by reason of any act of God, flood, fire, explosion, casualty or
      accident, or war, revolution, civil commotion, acts of public enemies,
      blockage or embargo, or any law, order or proclamation of any government
      not existing on the Effective Date, failure of unaffiliated suppliers to
      provide materials, equipment or machinery, interruption of or delay in
      transportation, strike or labor disruption, or other cause, whether
      similar or dissimilar to those above enumerated, beyond the commercially
      reasonable control of such Party.

                              ARTICLE 28 - INSURANCE

28.1  PSIMEDICA INSURANCE

      From the start of the commercial phase of this Agreement and for a period
      of four years after the expiration or other termination hereof, pSiMedica
      shall maintain in force and effect product liability insurance issued by a
      reputable insurance company with a rating reasonably satisfactory to QSA.
      Such insurance shall (a) insure against Damages resulting from or caused
      by (or claimed to be resulting from or caused by) the operation or use of
      any Medical Devices marketed or distributed by pSiMedica, and (b) shall
      have coverage limits of not less than U.S. $8,000,000 per occurrence and
      U.S. $8,000,000 in the aggregate. Within 15 days after the execution of
      the Commercial Phase of this Agreement, pSiMedica will deliver to QSA
      copies of all policies effecting such insurance (in English) with a
      certificate (in English) of pSiMedica's insurance broker stating that all
      premiums then due have been paid.

                                       32
<PAGE>

      It is understood that pSiMedica shall establish separate insurance cover
      for the risks associated with the period of clinical trials for each
      individual clinical trial. pSiMedica will deliver to QSA copies of all
      policies effecting such insurance (in English) with a certificate (in
      English) of pSiMedica's insurance broker stating that all premiums then
      due have been paid.

28.2  QSA INSURANCE

      QSA agrees, at QSA's expense, to maintain general liability, business
      interruption (for at least $2 million) and property and casualty insurance
      covering loss or damage to:

      (i)   the Facility;

      (ii)  any asset owned by pSiMedica in the possession of QSA under this
            Agreement, including the Hot Cell(s) and Equipment; and

      (iii) QSA's facility located at Braunschweig, Germany, as the case may be.

      Such insurance policy shall designate pSiMedica as loss payee in the event
      of any loss or damage involving any asset owned by pSiMedica and shall
      name pSiMedica as an additional insured. QSA agrees that such insurance
      shall be replacement value insurance for all property owned by pSiMedica.
      QSA shall, upon request, provide to pSiMedica a certificate of insurance
      designating pSiMedica as loss payee in event of any loss or damage covered
      by sub-clause (ii) of this Article, provided that any proceeds so received
      as a result of less than a total loss shall be used to repair such damaged
      or destroyed assets, including, but not limited to, the Hot Cell(s) and
      the Equipment. Any insurance proceeds held by QSA pursuant to this Article
      shall be used to repair or replace such damaged Facility and QSA shall
      give pSiMedica thirty (30) days advance notice of any termination or
      cancellation of such coverage. This Article shall survive termination of
      this Agreement with respect to sub-clause (ii) of the first sentence of
      this Article.

      In addition, during the Term of the Commercial Phase of this Agreement and
      for a period of four years after the expiration or other termination
      hereof, QSA shall maintain in force and effect product liability insurance
      issued by a reputable insurance company with a rating reasonably
      satisfactory to pSiMedica. Such insurance shall (a) include coverage
      insuring against Damages resulting from or caused by (or claimed to be
      resulting from or caused by) the operation or use of any Source shipped or
      repaired by QSA (b) shall have coverage limits of not less than U.S.
      $8,000,000 per occurrence and U.S. $8,000,000 in the aggregate, and shall
      name pSiMedica as an additional insured. Within 15 days after the
      execution of the Commercial Phase of this Agreement, QSA will deliver to
      pSiMedica copies of all policies effecting such insurance (in English)
      with a certificate (in English) of QSA's insurance broker stating that all
      premiums then due have been paid.

                                       33
<PAGE>

                            ARTICLE 29 SEVERABILITY

29.1  INVALID PROVISIONS

      If any provision or term of this Agreement is found unenforceable under
      any of the laws or regulations applicable thereto, all other conditions
      and provisions of this Agreement shall nevertheless remain in full force
      and effect so long as the economic or legal substance of the Agreement or
      transactions contemplated herein are not affected in any manner materially
      adverse to any Party. Upon such determination that any term or other
      provision is invalid, illegal or incapable of being enforced, the Parties
      hereto shall negotiate in good faith to modify this Agreement to effect
      the original intent of the Parties as closely as possible in a mutually
      acceptable manner, in order that the transaction contemplated hereby be
      consummated as originally contemplated to the greatest extent possible.

                               ARTICLE 30 GENERAL

30.1  ENTIRE AGREEMENT

      This Agreement, including the Schedules hereto which are incorporated
      herein, constitute the entire agreement of the Parties with respect to the
      subject matter hereof and supersedes all proposals, oral or written, and
      all negotiations, conversations, or discussions. This Agreement may not be
      modified, amended, rescinded, canceled or waived, in whole or in part,
      except by written amendment signed by both Parties hereto.

30.2  PUBLICITY

      The Parties agree that, except as may otherwise be required by applicable
      laws, regulations, rules or orders, no information concerning this
      Agreement and the transactions contemplated herein shall be made public by
      either Party without the prior written consent of the other, which consent
      shall not be unreasonably withheld. In the event either Party decides to
      issue a press release announcing the execution of this Agreement, it shall
      not do so without the prior written approval of the other Party.

      A copy of any proposed press release shall be provided to the other Party
      at least three (3) business days prior to any proposed dissemination. The
      Parties agree that they will use reasonable efforts to coordinate the
      initial announcement or press release relating to the existence of this
      Agreement.

30.3  EXPORT CONTROL

      The Parties understand that materials and information resulting from the
      performance of this Agreement may be subject to export control laws and
      that each Party is responsible for its own compliance with such laws.
      pSiMedica agrees that the cost of exporting Sources from Germany at its
      request shall be the responsibility of pSiMedica.

                                       34
<PAGE>

30.4  DISPUTE RESOLUTION

      (i)   In the event that, at any time during the term of this Agreement, a
            disagreement, dispute, controversy or claim should arise relating to
            scientific or technical issues in connection with QSA's performance
            under this Agreement, the Parties will attempt in good faith to
            resolve their differences for sixty (60) days. If, after sixty (60)
            days, the Parties are unable to resolve such dispute, the Parties
            shall refer the matter to a third Party consultant with expertise in
            the scientific or technical area of dispute for sixty (60) days. In
            the event such consultant is unable to work out a resolution of the
            issue with the Parties, the Parties shall within 30 days submit the
            matter to binding arbitration in Frankfurt, Germany to be undertaken
            pursuant to the applicable rules of the London Court of
            International Arbitration.

      (ii)  In the event that, at any time during the term of this Agreement, a
            disagreement, dispute, controversy or claim should arise out of or
            relating to the interpretation of or performance under this
            Agreement, or the breach, or invalidity thereof other than a dispute
            relating to scientific or technical issues in connection with QSA's
            performance under this Agreement covered by Article 30.4 sub-clause
            (i) above, the Parties will attempt in good faith to resolve their
            differences by referring the matter to the Chief Executive Officers
            of the Parties (or their designees) for sixty (60) days, following
            which if the matter is not resolved it will be submitted to
            alternative dispute resolution in Frankfurt, Germany to be
            undertaken pursuant to the applicable rules of the London Court of
            International Arbitration.

      (iii) The dispute resolution tribunal shall be composed of three
            arbitrators. The language of the arbitration shall be English. Under
            the LCIA Rules which are deemed to be incorporated by reference into
            this Agreement, the arbitrators shall resolve any dispute arising
            out of or in connection with this Agreement, including any questions
            regarding its existence, validity or termination.

30.5  ESSENCE

      Time is of the essence in this agreement.

                          ARTICLE 31 - APPLICABLE LAW

31.1  APPLICABLE LAW

      This Agreement shall be governed and construed in accordance with the laws
      of Germany. The Convention on the International Sale of Goods of April 11,
      1980 (CISG) and the German Law transforming the CISG into national law
      shall not apply.

                                       35
<PAGE>

IN WITNESS WHEREOF the Parties hereto have executed this Agreement as of the
date first above written.

                                        AEA TECHNOLOGY QSA GMBH

                                        By: /s/Ranier Lambrich
                                            ------------------------------------
                                            Dr. Rainer Lambrich
                                            Geschaftsfuhrer

                                        PSIMEDICA LTD

                                        By: /s/Roger Brimblecombe
                                            ------------------------------------
                                            Dr. Roger Brimblecombe
                                            Chairman

                                       36
<PAGE>

                          SCHEDULE A DEVELOPMENT PHASE

This schedule is subject to any requirement contained in schedules B, C and D.
Any changes to such requirements will alter the provisions of schedule A.

At the Effective Date the ongoing development phase continues to optimise the
production of irradiated P-32 BioSilicon(TM) for animal and potential human
trials and the development of automation to the handling processes necessary to
produce the finished Sources.

The Development Phase has two key milestones

      1.    Pilot plant development for supply of circa 8 patient doses into a
            Phase IIa human clinical trial expected to commence May 2004.

      2.    Main plant development with process scale up to deliver [***] into a

Phase IIb human clinical trial expected to commence [***]. Design capacity for
commercial production - [***].

The initial development programme will indicate the process by which sources
will be manufactured viz) method of slurry creation, or dry powder dispensing,
and sterilization method. The time frame for this is estimated to be by end
March 2004.

Flexibility to react to pSiMedica requirements is an important concept in the
Development Phase and at the Effective Date work was also being defined to
develop a Source dose-vial containment, shielding and Source transport
container.

Progress of the Development Phase projects is disseminated via monthly reports
and changes/additions to the programmes are actioned after receipt of written
instructions from PSiMedica.

Additional development activities outside of the scope of the initial
development programme and provision of the Pilot Plant facility will be agreed
under protocol by both parties and billed at the following contract rates

Facility Programme billing rates:

[***]

                                       37
<PAGE>

                        SCHEDULE B FACILITY DESCRIPTION

[*** five pages excluded ***]

                                       38
<PAGE>

             SCHEDULE C PRODUCT DESCRIPTION (FOR PHASE IIA PRODUCT)

32P BioSilicon 20um High P is a source component consisting of 20um particles of
acid treated Silicon containing Phosphorus-32.

The device will be provided `for single use only' as a dry powder for use in
interstitial brachytherapy. It is supplied as a sterile powder in 10ml
borosilicate glass vials with a 20mm rubber stopper and aluminium overseal. The
glass vial is contained for transportation within a lead-shielded Perspex "vial
carrier".

Specific activity of P-32 BioSilicon 20um High P at reference date will be 1.4
+/- 0.1 MBq per mg.

Nominal activity: Each vial will contain 250 +/- 25 MBq of P-32 BioSilicon 20um
High P.

Prior to use the device will be reconstituted in an injectable suspending
aqueous formulation (known as FM27v2) at up to 50 mg/ml BioSilicon
microparticles.

It is anticipated that the Source will be a component of a Device kit that is
approved for the delivery of patient doses.

First clinical trials will follow a low dose range strategy of ~ 4 MBq per ml of
tumour. The 32P-BioSilicon(TM) microparticles will be administered
interstitially using a specially designed shielded syringe, which is under
development. This will minimise the possibility of environmental contamination
with radionuclide during the injection process, ensure operator safety and allow
site directed delivery using assisting techniques such as ultrasound or
tomography.

Radionuclide purity:

32P BioSilicon 20um High P is nuclear reactor produced by the neutron
bombardment of 31P. At the time of calibration it contains not less than 99%
Phosphorus 32

Radiochemical purity: >95%

Chemical purity:

32P BioSilicon 20um High P is tested for the following metals, Na, Mg, Al, K,
Ca, Cr, Mn, Fe, Ni, Cu (also Mo & Co) and contains below 10 ppm of each
impurities.

It is recognised by both Parties that the product details may change as the
Development programme progresses. All changes will be as a result of mutual
agreement and confirmed in writing, between the parties.

                                       39
<PAGE>

                        SCHEDULE D SOURCE SPECIFICATIONS

At the Effective Date, the final specification and presentation of the Source(s)
has not been completely developed, however, the fundamental product details and
description of the said specification are understood, and are detailed in
Schedule C.

In addition, during the period of the Development Phase covered in Article 4,
pSiMedica may request alterations to the specifications in order to meet the
needs of:

            -     Product Improvement

            -     Product development difficulties

            -     Market changes

            -     Business strategy

A draft specification agreed by both Parties is incorporated into this Schedule
D. Changes to the specifications must be agreed in writing between the two
Parties and where justified, revisions to the Commercial Phase terms will be
allowed.

                                       40
<PAGE>

--------------------------------------------------------------------------------
AEA TECHNOLOGY                Specification                          [LOGO]
QSA GMBH        Specification for P-32 BioSilicon 20umHigh P      AEA TECHNOLOGY
BRAUNSCHWEIG                 Dokumentnummer:                          QSA
--------------------------------------------------------------------------------

DRAFT SPECIFICATION:

                  SPECIFICATION FOR P-32 BIOSILICON 20UMHIGH P

                                     DRAFT 1

                                  QS-DOC. NO.:

--------------------------------------------------------------------------------
Erstellt:

Name, Vorname / Funktion : Th

Datum                    :

Unterschrift             :
--------------------------------------------------------------------------------

Gepruft:

Name, Vorname / Funktion :

Datum                    :

Unterschrift             :
--------------------------------------------------------------------------------

Genehmigt

Name, Vorname / Funktion :

Datum                    :

Unterschrift:            :
--------------------------------------------------------------------------------

Uberprufungsintervall: alle 2 Jahre
Besonderheiten:        keine

                                       41
<PAGE>

--------------------------------------------------------------------------------
AEA TECHNOLOGY                Specification                          [LOGO]
QSA GMBH        Specification for P-32 BioSilicon 20umHigh P      AEA TECHNOLOGY
BRAUNSCHWEIG                 Dokumentnummer:                          QSA
--------------------------------------------------------------------------------
<TABLE>
<CAPTION>
<S>     <C>                        <C>                           <C>

----------------------------------------------------------------------------------------------
1.      MAT. NO.                   [Psi code No.]
----------------------------------------------------------------------------------------------
2.      DISTRIBUTOR
----------------------------------------------------------------------------------------------
3.      CODE                       PBSB.....
----------------------------------------------------------------------------------------------
4.      PRODUCT NAME               (32P)BioSilicon 20um High P
        COMPANY DISTRIBUTOR        PsiMedica
----------------------------------------------------------------------------------------------
5.      COMMERCIAL DESIGNATION     --
        CAS-NO.
----------------------------------------------------------------------------------------------
6.      DESCRIPTION                                               TARGET
----------------------------------------------------------------------------------------------
6.1     ACID TREATED SILICON CONTAINIG                            --
        [32P]PHOSPHORUS
        DRY STERILE POWDER
        IN VIALS WITH PUNCTURE STOPPER AND CRIMPED CAPS
----------------------------------------------------------------------------------------------
7.     CHEMICAL / PHYSICAL PROPERTIES / METHODS                   TARGET
----------------------------------------------------------------------------------------------
7.1    IDENTITY P-32 / LIQUID SCINTILLATION COUNTING              Beta max. energy not greater
                                                                  than 1.7 1MeV
----------------------------------------------------------------------------------------------
7.2    y-emitting impurities / y-spectrometry                     P-32 > 99 %
       AT REFERENCE DATE (RD)                                     Impurities
                                                                  < 1%
----------------------------------------------------------------------------------------------
7.3    SPECIFIC ACTIVITY P-32 AT RD
       LIQUID SCINTILLATION COUNTING                              (1.4 +/- 0.1) MBq/mg
       AFTER DISSOLVING AND DILUTION
----------------------------------------------------------------------------------------------
7.4    (mass or volume of formulant per vial) Tbd                 n.n.
----------------------------------------------------------------------------------------------
7.5    ACTIVITY AT RD / IONISATION CHAMBER MEASUREMENT            (250 +/- 25) MBq
----------------------------------------------------------------------------------------------
7.6    Chemical purity / (Tbd Psi)                                Tbd by PSi
----------------------------------------------------------------------------------------------
7.7    RADIOCHEMICAL PURITY / PER SE                              > 95%
----------------------------------------------------------------------------------------------

                                       42
<PAGE>

<CAPTION>
<S>    <C>                                       <C>
----------------------------------------------------------------------------------------------
8.     OTHER REQUIREMENTS
----------------------------------------------------------------------------------------------
9.     CERTIFICATE                               Batch No.;.... [batch code system tbd by PSi]
----------------------------------------------------------------------------------------------
10.    SAFETY DATA SHEET PURSUANT TO             --
       91/155/EWG
----------------------------------------------------------------------------------------------
11.    SHIPPING TERMS                            Shielded
----------------------------------------------------------------------------------------------
12.    STORAGE TERMS                             Shielded
----------------------------------------------------------------------------------------------
13.    REFERENCE DATE AND TIME                   Date (Day, Month, Year),
       LABELLING                                 12:00 (Singapore local time)
----------------------------------------------------------------------------------------------
14.    SHELF- LIFE                               Reference date +/- 2 days
----------------------------------------------------------------------------------------------
15.    PRODUCT PACKAGING                         P6 injection vial with puncture stopper
                                                 and crimped caps
----------------------------------------------------------------------------------------------
16. WRAPPING / SHIPPING PACKAGING                Typ A Shipping Packaging
----------------------------------------------------------------------------------------------
17. REDEMPTION/ DISPOSAL                         Product: Hazardous Waste
----------------------------------------------------------------------------------------------
18. MISCELLANEOUS                                --
----------------------------------------------------------------------------------------------
</TABLE>

                                       43
<PAGE>

                               SCHEDULE E PRICING

In accordance with Article 9.3, prior to the commencement of the Commercial
Phase, the Parties shall agree the price that shall be paid by pSiMedica for
each Source that QSA produces to Specification. [***].

At the Effective Date QSA is unable to provide definitive pricing schedules that
will be relevant to the supply of sources during the Commercial Phase, however,
good faith indications of the prices will be confirmed at the end of the
relevant portion of the Development Phase and prior to the commencement of the
Commercial Phase. The definitive pricing schedules will be communicated via an
amended Schedule E.

It is anticipated that pricing will vary by required batch size and that the
price schedules will reflect this fact. Source prices will be cited for
different order quantities, however, the prices will be dictated by the
effective number of Sources demanded per batch. Both Parties recognise that the
Facility will be designed to cope with a maximum Source throughput (Sources per
year) that will be agreed before the end of the Development Phase.

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}]]